

Title	Recent advances in the understanding of the aetiology and therapeutic strategies in burning mouth syndrome: Focus on the actions of cannabinoids
Authors	Pereira, Sónia R.;Tello Velasquez, Johana;Duggan, Sarah;Ivanisevic, Bojana;McKenna, Joseph P.;McCreary, Christine;Downer, Eric J.
Publication date	2020-02-24
Original Citation	Pereira, S. R., Tello Velasquez, J., Duggan, S., Ivanisevic, B., McKenna, J. P., McCreary, C. and Downer, E. J. (2020) 'Recent advances in the understanding of the aetiology and therapeutic strategies in burning mouth syndrome: focus on the actions of cannabinoids', European Journal of Neuroscience. doi: 10.1111/ejn.14712
Type of publication	Article (peer-reviewed)
Link to publisher's version	https://onlinelibrary.wiley.com/doi/abs/10.1111/ejn.14712 - 10.1111/ejn.14712
Rights	© 2020, John Wiley & Sons, Inc. This is the peer reviewed version of the following article: Pereira, S. R., Tello Velasquez, J., Duggan, S., Ivanisevic, B., McKenna, J. P., McCreary, C. and Downer, E. J. (2020) 'Recent advances in the understanding of the aetiology and therapeutic strategies in burning mouth syndrome: focus on the actions of cannabinoids', European Journal of Neuroscience, doi: 10.1111/ejn.14712, which has been published in final form at https://doi.org/10.1111/ejn.14712 . This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions.
Download date	2023-05-05 02:58:28
Item downloaded from	http://hdl.handle.net/10468/9753



University College Cork, Ireland
Coláiste na hOllscoile Corcaigh

DR. ERIC J. DOWNER (Orcid ID : 0000-0002-6012-2291)

Article type : Special Issue Review

“Recent advances in the understanding of the aetiology and therapeutic strategies in burning mouth syndrome: focus on the actions of cannabinoids”

Sónia R. Pereira^a, Johana Tello Velasquez^a, Sarah Duggan^a, Bojana Ivanisevic^b, Joseph P. McKenna^b, Christine McCreary^b and Eric J. Downer^{a,*}

^a*Discipline of Physiology, School of Medicine, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin 2, Ireland*

^b*Cork University Dental School and Hospital, University College Cork, Cork, Ireland*

*Correspondence to: Dr. Eric J. Downer, School of Medicine (Physiology), Trinity Biomedical Sciences Institute, Trinity College Dublin, 152-160 Pearse Street, Dublin 2, Ireland. Email: edowner@tcd.ie

Running title: Potential benefit of cannabinoids in BMS

46 pages, 2 figures and 3 tables

14,649 words in the whole manuscript; 172 words in the Abstract

Keywords: neuropathic orofacial pain, burning mouth syndrome, immunological, hormonal, psychological, therapeutics, cannabinoids, cannabis, endocannabinoid system

Abstract

Burning mouth syndrome (BMS) is a neuropathic pain disorder associated with a burning sensation on oral mucosal surfaces with frequently reported xerostomia, dysgeusia and tingling or

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the [Version of Record](#). Please cite this article as [doi: 10.1111/ejn.14712](#)

[10.1111/ejn.14712](#)

paraesthetic sensations. However, patients present no clinically evident causative lesions. The poor classification of the disorder has resulted in a diagnostic challenge, particularly for the clinician/dentist evaluating these individuals. Major research developments have been made in the BMS field in recent years to address this concern, principally in terms of the pathophysiological mechanisms underlying the disorder, in addition to therapeutic advancements. For the purpose of this review, an update on the pathophysiological mechanisms will be discussed from a neuropathic, immunological, hormonal and psychological perspective. This review will also focus on the many therapeutic strategies that have been explored for BMS, including antidepressants/antipsychotics, nonsteroidal anti-inflammatories, hormone replacement therapies, phytotherapeutic compounds and non-pharmacological interventions, overall highlighting the lack of controlled clinical studies to support the effectiveness of such therapeutic avenues. Particular focus is given to the cannabinoid system, and the potential of cannabis-based therapeutics in managing BMS patients.

1. Introduction

Primary, or idiopathic burning mouth syndrome (BMS), is defined by the International Headache Society as an “intraoral burning or dysaesthetic sensation, recurring daily for more than two hours per day over more than three months, without clinically evident causative lesions”. In addition to the oral burning or stinging sensation of the tongue, lips or other oral mucosal surfaces, BMS patients frequently report dry mouth (xerostomia), taste disturbance (dysgeusia) and tingling or paraesthetic sensations (IHS, 2018). Although some reports indicate a decrease in unstimulated salivary flow in BMS (Lee *et al.*, 2015), recent data suggest that the alteration in both unstimulated and stimulated salivary flow is associated with the medication used by the patient(s), and the presence of other systemic diseases, rather than the syndrome *per se* (Acharya *et al.*, 2018b). Moreover, Lee *et al.* (2015) did not identify significant differences in salivary gland function when using salivary scintigraphy. According to ICD-10 codes, BMS is also known as glossodynia, orodynia, stomatodynia, and sore or burning tongue, and is currently described by the International Headache Society as a “painful cranial neuropathy”, highlighting the neuropathic mechanisms underlying the disorder. BMS was previously viewed as a “psychogenic pain” due to its close association with psychological factors including anxiety, depression and carcinophobia (Browning *et al.*, 1987). This shift in classification has been increasingly supported by data from more recent histological, neurophysiological, brain imaging and quantitative sensory testing, that

provide evidence of neuropathic alterations in BMS patients, as reviewed extensively elsewhere (Jaaskelainen & Woda, 2017). A secondary BMS may also occur due to local (candidiasis, lichen planus, hyposalivation) or systemic (medication-induced, anaemia, deficiencies of vitamin B12 or folic acid, Sjögren's syndrome, diabetes) causes. In the case of secondary BMS, once the underlying factors are treated, the symptoms cease (IHS, 2018). Primary BMS is the focus of this review.

1.1. Clinical features of BMS

The clinical features of BMS vary from patient to patient, including variations in pain intensity and duration. The onset of symptoms can be gradual or sudden, with no identifiable trigger. However, some cases have been linked to dental procedures, trauma, new medication use, illness or stressful life events (Bender, 2018). In most cases the pain progresses from mild to moderate throughout the day (Lopez-Jornet *et al.*, 2015b), and may be continuous or intermittent, most commonly affecting the anterior two-thirds of the tongue; however, the pain may impact other mucosal surfaces. Furthermore, the symptoms tend to be bilateral and symmetric (Wada *et al.*, 2017; Bender, 2018). Based on these differences, some authors have classified different subtypes of BMS (Moghadam-Kia & Fazel, 2017), nonetheless no clear classification has been validated to date. More recent reports to divide BMS into three major categories depending on the neuropathic origin of the disorder include the following: (i) peripheral small fiber neuropathy, (ii) trigeminal neuropathy, and (iii) hypofunction of dopaminergic neurons in the basal ganglia (Jaaskelainen & Woda, 2017).

Several factors can modify the painful symptoms reported in BMS, including the consumption of food/drink, speech (Bender, 2018) and sleep quality (Lopez-Jornet *et al.*, 2015a). Even though some patients report pain relief while eating, most patients avoid hot, spicy, acidic food/drinks or alcoholic beverages, since they intensify the pain sensation (Bender, 2018). Poor sleep quality is frequently reported in BMS and correlates with syndrome severity (Adamo *et al.*, 2018). Furthermore, stress and fatigue have a major impact on pain intensity, and the disruption of the circadian rhythm can affect inflammation (Kizaki *et al.*, 2015), pain thresholds and pain sensitivity (Haack *et al.*, 2019).

1.2. Diagnosis of BMS

The diagnosis of primary BMS is a clinical challenge and can only be established by exclusion of other disorders that may cause oral cavity pain (Moghadam-Kia & Fazel, 2017; Bender, 2018), in particular Sjögren's syndrome (Aljanobi *et al.*, 2017). A clinical evaluation is made when the pain complaints are consistent with the oral burning pain sensation, and there is no physical pathology associated with the complaint. To establish a diagnosis, the clinician must gather a comprehensive medical and dental history, detailing the characteristics of the pain (onset, duration, anatomical location, exacerbating/ameliorating factors), current medication use, coexisting manifestations of xerostomia, denture use and history of psychiatric disease (anxiety disorder, depression, personality disorder). A history of previous upper respiratory tract infections, middle ear disease or surgery associated with damage to the chorda tympani nerve (branch of cranial nerve VII) should also be recorded (Bender, 2018). This is particularly relevant since taste input mediated by the chorda tympani nerve is known to inhibit the trigeminal somatic input at the central nervous system (CNS). Therefore, BMS may result from the loss of the normal chorda tympani inhibitory control over somatic afferents, thus intensifying trigeminal sensations including pain (Bartoshuk *et al.*, 2005). A physical evaluation should also investigate signs of parafunctional habits, erythema, irritation, mucosal ulceration or other abnormalities. Furthermore, laboratory studies should collate blood cell counts, iron, zinc and vitamin levels, fasting blood glucose levels/glycosylated haemoglobin and thyroid function (Moghadam-Kia & Fazel, 2017; Bender, 2018).

Due to difficulties in diagnosing BMS, patients commonly attend several clinical consultations prior to a definitive diagnosis, resulting in delays in treatment initiation and commonly exacerbating anxiety. Hence, further characterization of BMS is needed, in addition to clear diagnostic tools. This is particularly relevant taking into consideration the older age demographic of BMS patients, usually with multimorbidity and polypharmacy that increases the risk of adverse drug effects commonly associated with the symptoms of BMS (hyposalivation, dysgeusia) (Ni Riordain *et al.*, 2019). With that aim, several attempts have been made to identify specific biomarkers for the disorder. Indeed, some promising candidates include interleukin (IL)-18 (a pro-inflammatory cytokine associated with interferon-gamma (IFN- γ) synthesis (Banu *et al.*, 2015)), kallikrein (Klk) 13 (a serine protease involved in regulating inflammation (Ehrenfeld *et al.*, 2018)) and α -amilase (a stress-related enzyme (Imura *et al.*, 2016)). Such candidates are upregulated in saliva from BMS patients compared to control subjects, and may be relevant to the

pathophysiology of the disease (Imura *et al.*, 2016; Ji *et al.*, 2017). Furthermore, recent technological advances in clinical neurophysiology suggest that electrogustatometry readings (for taste disturbances) and quantitative sensory thresholds (QST) (for detection thresholds) may act as sensitive diagnostic tools, or tools that can be used to identify BMS subtypes (Jaaskelainen & Woda, 2017).

1.3. Epidemiology and aetiology of BMS

Depending on the study, BMS prevalence ranges from 0.7% to 15% in the general population (Tait *et al.*, 2017), and such variability is due to the lack of objective diagnostic criteria and clear distinction between idiopathic and secondary BMS subtypes. In fact, a more recent study estimated a lower prevalence of 0.1% when using more stringent criteria for diagnosis (Kohorst *et al.*, 2015). Although BMS may affect younger women and men, it is most prevalent at older ages, especially in postmenopausal women (Kohorst *et al.*, 2015). Age-adjusted incidence is higher in women than men (18.8 vs 3.7/100,000 person-year), with the highest values between 50 to 89 years of age (maximum of 70.3/100,000 person-year between 70 to 79 years of age) (Kohorst *et al.*, 2014). The ratio of male:female BMS is approximately 1:4, and hence the main predictive factors for BMS onset are age and sex (Rabiei *et al.*, 2018). Furthermore, sociodemographic studies commonly link BMS onset with a stressful life event, particularly unemployment (Adamo *et al.*, 2015). Unfortunately the prognosis for such patients is poor, with a significant impact on quality of life (QOL) (Kim & Kho, 2018).

Despite much research investigating BMS, its aetiology still remains unclear. It is believed to be a multifactorial condition that involves alterations in the expression profile of hormones and local neuroactive steroids related to menopause and anxiety states. This, combined with external or internal factors (environmental, medical procedures, pharmacological or systemic disease-related agents), may be deleterious to the function of the nervous system, especially in genetically susceptible individuals (Chimenos-Kustner *et al.*, 2017; Jaaskelainen & Woda, 2017). Indeed, some authors have categorized BMS risk factors as local and systemic (**Table 1**) (Bender, 2018); local factors can induce oral burning sensation via direct irritation, ischemia or compression of the oral tissue, while systemic factors are linked to axonal damage (Jaaskelainen & Woda, 2017). Overall, both local and systemic factors may impair neural function (Robinson, 2000; Kang *et al.*, 2017), and once this occurs, even if the causative factors are removed/treated (secondary BMS excluded), the damage is not reverted (Jaaskelainen & Woda, 2017). The same applies to hormone

replacement therapy, which may be effective at reverting neuropathic changes at early stages, but ineffective at later stages when irreversible fibre damage has taken place (Jaaskelainen & Woda, 2017). Genetic susceptibility should also be further investigated in BMS since polymorphisms in IL-1 β has been linked to BMS pathogenesis (Guimaraes *et al.*, 2006). Furthermore, some studies point to a heightened taste perception and increased number of fungiform papillae on the tongue of patients, linking the taste receptor TAS2R38 gene to BMS susceptibility (Kolkka-Palomaa *et al.*, 2015). Reports of xerostomia and skin disease or symptoms (rosacea, eczema and dry skin) have also been strongly linked to BMS (Acharya *et al.*, 2018a). At the CNS, dopamine D2 receptor polymorphism C957T has also been associated with BMS aetiology, since such polymorphisms result in reduced synaptic dopamine concentrations and a subsequent reduction in pain inhibition (Jaaskelainen *et al.*, 2014).

2. Pathophysiology of BMS

There have been major developments in BMS research in recent years, which has resulted in classification shifts, particularly from psychogenic to neuropathic (2018; Jaaskelainen, 2018). In fact, although anxiety and depression are reported in BMS patients, such conditions commonly arise only after BMS onset (Sikora *et al.*, 2018). Moreover, much evidence links BMS with lesions and/or dysfunction in the CNS and peripheral nervous system (PNS) (Valenca *et al.*, 2015). In addition, both the immune and endocrine systems are closely associated with the onset and progression of BMS (Koike *et al.*, 2014). Indeed, allergies (Marino *et al.*, 2009; Acharya *et al.*, 2018a), and genotypes associated with inflammatory diseases (Guimaraes *et al.*, 2006; Kim *et al.*, 2017), confer a higher risk for BMS. Overall, the pathophysiology of BMS is complex, with multiple mechanisms associated with BMS pathogenesis (Bender, 2018). For the purpose of this review, these pathophysiological mechanisms will be discussed under four subject areas; neuropathic, immunological, hormonal and psychological (summarised in **Figure 1**). It is important to note that although these mechanisms have been correlated with BMS, much of this data is from cross-sectional study analysis. Therefore, it is not clear if these mechanisms are present prior to BMS development, or if they manifest as a result of BMS. To overcome this limitation, further studies using longitudinal approaches are needed.

2.1. Neuropathic

Much data demonstrate relevant structural and functional changes in both the CNS and PNS of patients with BMS (Valenca *et al.*, 2015). Indeed, significant alterations in the structure/function of both the hippocampus and the medial prefrontal cortex (mPFC) have been reported in BMS patients, compared to healthy individuals (Khan *et al.*, 2014; Wada *et al.*, 2017). Specifically, Khan *et al.*, (2014) report an increase in hippocampal gray matter volume (GMV) in BMS patients, alongside a decrease in the mPFC (Khan *et al.*, 2014). The latest published data indicate a decrease in GMV in the thalamus and middle temporal gyrus of BMS patients when compared to control subjects, in addition to a decrease in cerebral blood flow in the middle temporal gyrus and insula (Liu *et al.*, 2015; Lee *et al.*, 2019). Such thalamic atrophy may play a key role in BMS pathogenesis since this area mediates nociceptive signalling to the cortex, and thalamic lesions are associated with chronic pain disorders (Giesecke *et al.*, 2004). In support of this, recent data from both Lee *et al.*, (2019) (Lee *et al.*, 2019) and Sinding *et al.*, (2016) (Sinding *et al.*, 2016) correlates pain intensity with a decrease in GMV in BMS patients. Moreover, a decrease in cerebral blood flow may also correlate with the depressive symptomatology in BMS (Liu *et al.*, 2015).

Functional magnetic resonance imaging (MRI) studies indicate several differences between BMS patients and healthy subjects. Indeed, BMS patients exhibit higher functional connectivity between the mPFC and areas associated with pain processing (anterior insula cortex and anterior cingulate cortex), while in the hippocampus, a decreased connectivity with areas associated with working memory and attention (dorsolateral prefrontal cortex) is reported (Khan *et al.*, 2014) (**Figure 1**). Strikingly, those differences increase from morning to afternoon, and correlate with a pain/burning state, which may explain the exacerbation of BMS symptoms during the day (Khan *et al.*, 2014). Such structural and functional alterations may be linked to anxiety/depression that patients endure related to their ongoing pain (Khan *et al.*, 2014).

CNS involvement in BMS is also evident in neurophysiological studies that link this disorder to dysfunction in the striatal dopamine system (Hagelberg *et al.*, 2003) (**Figure 1**). The depletion of dopamine in the putamen results in deficient pain inhibition in the trigeminal brainstem complex in BMS patients (Hagelberg *et al.*, 2003; Wood, 2008). In support of this, BMS patients exhibit low serum levels of neurokinin A, a neuropeptide associated with pain and inflammation (Boras *et al.*, 2010). Furthermore, reduced dopaminergic tone may also be associated with the personality traits and/or psychiatric disorders commonly reported in BMS (Taiminen *et al.*, 2011).

Neural function can be assessed by testing the blink reflex via stimulation of trigeminal nerve (cranial nerve V) branches, specifically the supraorbital, mental and lingual nerves. Interestingly, with this approach, BMS has been correlated with trigeminal dysfunction in approximately 20% of the patients (Jaaskelainen & Woda, 2017). Furthermore, data from Puhakka and colleagues (2016) (Puhakka *et al.*, 2016) indicate that BMS is linked to large fibre neuropathy in the form of elevated vibratory detection thresholds and enhanced mental nerve blink reflexes. The electrical thresholds that elicit the blink reflex are higher in BMS patients than in control subjects, and these findings suggest trigeminal tactile A β fibre hypofunction (Puhakka *et al.*, 2016; Jaaskelainen & Woda, 2017). BMS is also related to alterations in taste and sensory systems, as patients frequently report bitter, metallic or foul tastes (Jaaskelainen & Woda, 2017; Bender, 2018). Indeed, electrogustometry studies indicate that BMS patients have lower taste sensitivity in fungiform and foliate taste buds (Braud *et al.*, 2017). Furthermore, Bartoshuk *et al.*, (2005) hypothesise that BMS may result from a convergence of pain and taste sensations, and that this may be due to the loss of inhibition of the trigeminal nerve due to chorda tympani nerve damage (Bartoshuk *et al.*, 2005). Due to the close physiological interaction between the trigeminal and facial nerves, damage to either nerve may influence the function of the other (Bartoshuk *et al.*, 2005; Schobel *et al.*, 2012).

BMS has also been linked to peripheral small fibre damage (**Figure 1**) as shown by psychophysical QST or neurophysiological recordings of thermal and pain-evoked potentials, in addition to nociceptive reflexes (Jaaskelainen & Woda, 2017). Although the first thermal QST found lower tolerance to painful heat stimulus only at the tip of the tongue in BMS (Grushka *et al.*, 1987), recent studies indicate broader dysfunction of the thermal detection thresholds at the tongue mucosa (Puhakka *et al.*, 2016; Hartmann *et al.*, 2017) that correlate with symptom duration (Watanabe *et al.*, 2018). In most cases, hypoesthesia or anaesthesia to innocuous and painful thermal stimuli are recorded (Forssell *et al.*, 2002; Puhakka *et al.*, 2016). However, reports elsewhere indicate cold hyperalgesia in BMS patients (Yilmaz *et al.*, 2016; Hartmann *et al.*, 2017), and despite contradictory findings, the lower reactivity to thermal stimuli may be correlated with a reduced volumetric activation throughout the brain (Albuquerque *et al.*, 2006). In terms of the type of fibres affected, even though some patients exhibit C fibre hypofunction within the lingual nerve, it is more common to detect small myelinated A δ fibre damage/hypofunction in BMS (Puhakka *et al.*, 2016). This suggests that decreased signalling of A δ fibres results in a deficient inhibition of the unmyelinated C fibres, and their continuous signalling may be the cause of the burning pain sensation perceived in BMS (Puhakka *et al.*, 2016; Jaaskelainen & Woda, 2017;

Moura *et al.*, 2018). These findings are supported by neuropathological investigations using oral mucosal biopsies from BMS patients, which report a reduced density of epithelial small fibres and sub-papillary tongue nerve fibres, while preserving the subepithelial large fibres (Puhakka *et al.*, 2016). The damage may result from consumption of excessively hot food or beverages, or from common dental procedures (Bender, 2018). Dysregulation in mucosal blood flow has also been reported in BMS patients, and the increased vasoreactivity in BMS might either result from, or affect, the neurovascular microcirculatory unit (Heckmann *et al.*, 2001).

It should be noted that the activity of several receptors located on the tongue is dysregulated in BMS. Indeed, the classical G protein-coupled cannabinoid receptor-1 (CB₁) is downregulated in the tongue epithelia in BMS patients, while cannabinoid receptor-2 (CB₂), and the transient receptor potential vanilloid 1 (TRPV1) receptor, are upregulated (Yilmaz *et al.*, 2007; Borsani *et al.*, 2014). Both receptor types are relevant in the endogenous cannabinoid (endocannabinoid; eCB) system, since CB_{1/2} are “classical” and TRPV1 “non-classical” receptors for eCBs (Di Marzo *et al.*, 2015) (discussed in **section 4**). Likewise, both nerve growth factor (NGF) (Yilmaz *et al.*, 2007) and artemin (Shinoda *et al.*, 2015) are overexpressed in BMS patients, which is important as both of these neurotrophic factors are regulators of TRPV1 expression. The upregulation of TRPV1 is particularly relevant since this receptor is commonly activated by noxious heat and capsaicin (chili pepper extract), and its expression correlates with ongoing pain symptoms (Yilmaz *et al.*, 2007). Similarly, enhanced immunoreactivity of the sensory purinergic receptor P2X3 has been reported in BMS, which is primarily expressed on small neurons of sensory ganglia (Beneng *et al.*, 2010). A higher density of fungiform papillae usually leads to a higher taste perception that may lower tolerance to bitter foods and irritants (Bartoshuk *et al.*, 2005). However, there is still controversy regarding dysregulation of its expression; however the distribution of fungiform papillae appear asymmetrical on both sides of the tongue in BMS patients, thus indicating an asymmetrical innervation (Naud *et al.*, 2018). The taste thresholds within both the fungiform and foliate papillae are also impaired in BMS patients (Braud *et al.*, 2017).

2.2. Immunological

Although few studies have been published focusing on the role of immunological factors in BMS, there is growing evidence that a dysregulation of inflammatory mechanisms is a key factor in disease onset and development (**Figure 1**). The dysregulation of several inflammatory mediators in both plasma and saliva from BMS patients, when compared to control subjects

(Simčić *et al.*, 2006; Chen *et al.*, 2007; Pekiner *et al.*, 2008; Pezelj-Ribaric *et al.*, 2013; Barry *et al.*, 2018a), strengthens the hypothesis of a neuroinflammatory mechanism.

Pro-inflammatory cytokines and chemokines contribute to nociceptive signalling, and their expression profiles are altered in neuropathic pain disorders and under conditions of stress (Lechner & von Baehr, 2015; Lewis *et al.*, 2017). Indeed, cytokine imbalance may increase the risk of depressive symptomatology by modulating central neurotransmitter systems (Liu *et al.*, 2012). In agreement with this, recent data from a pilot study in our laboratory demonstrate that the expression of the pro-inflammatory chemokine IL-8 is enhanced in plasma isolated from BMS patients, when compared to control subjects (Barry *et al.*, 2018a). The same study also indicates a correlation between the ratio of plasma IL-8:IL-10 and depressive symptomatology in BMS patients (Barry *et al.*, 2018a). Interestingly, genetic polymorphisms related to the overexpression of the cytokine IL-1 β are correlated with BMS development (Guimaraes *et al.*, 2006) and psychological asthenia (Kim *et al.*, 2017), and similarly, the expression of the IL-18 cytokine (a member of the IL-1 family) is also upregulated in BMS saliva (Ji *et al.*, 2017). Although saliva is a promising non-invasive methodology to assess BMS, the data from saliva assessment in BMS is more variable, with some studies not identifying differences in salivary cytokines (Boras *et al.*, 2006; Suh *et al.*, 2009). However, a body of research indicates that the expression of the inflammatory cytokines IL-6 (Chen *et al.*, 2007), IL-2 and tumor necrosis factor alpha (TNF- α) (Pekiner *et al.*, 2008) are reduced in plasma, while significantly upregulated in saliva (Simčić *et al.*, 2006; Pezelj-Ribaric *et al.*, 2013), in BMS cohorts, when compared to healthy subjects. The poor classification of the disease, and differences in the methodologies adopted in each study, may explain the variability in published data related to cytokine signatures in both BMS plasma and saliva.

In the search for BMS biomarkers in saliva, several inflammatory-related molecules have also been proposed, with evidence that their expression profiles are altered in BMS; namely Klk (Ji *et al.*, 2017) and α -amilase (Imura *et al.*, 2016; Nosratzahi *et al.*, 2017). In addition, the expression of membrane-bound mucin 1 (MUC1) in oral epithelial cells (Kang *et al.*, 2017), α -enolase (Ji *et al.*, 2017) and cystatin (Cabras *et al.*, 2019) are increased in saliva from BMS patients. This is particularly relevant since both mucus gel production (Kang *et al.*, 2017) and α -enolase (Ji *et al.*, 2017) participate in the first line immune defence against pathogens, and a higher neutral cystatin reflects a mechanism of defence against ongoing inflammatory processes (Cabras *et al.*, 2019). Reports also indicate that the expression of neuropeptides in saliva are also dysregulated in BMS.

Among them, NGF is upregulated, and substance P (SP) (Borelli *et al.*, 2010) and calcitonin gene related peptide (CGRP) are downregulated (Zidverc-Trajkovic *et al.*, 2009). NGF can trigger mast cell degranulation at nerve lesion sites that, in turn, may exacerbate its expression in BMS (Borelli *et al.*, 2010). Both SP and CGRP are associated with neurogenic pain and are secreted simultaneously. Their reduced expression is indeed a distinct feature from other painful conditions (Zidverc-Trajkovic *et al.*, 2009; Borelli *et al.*, 2010). Opiorphin, an inhibitor of enkephalin-inactivating peptidases (Wisner *et al.*, 2006), is also upregulated in saliva from BMS patients, which may represent an adaptive response to chronic pain (Salaric *et al.*, 2017). In addition, Boucher *et al.*, (2017) (Boucher *et al.*, 2017) found significant differences in the expression of opiorphin in blood samples from BMS patients, which may reflect a systemic dysregulation related to environmental stress conditions and psychological distress.

Another poorly investigated pathophysiological mechanism in BMS is the imbalance in the eCB system (discussed in **section 4**), which consists of endogenous ligands for the cannabinoid receptors (Storozhuk & Zholos, 2018). Recent data from our laboratory suggests that the expression profile of the non-cannabinoid N-acylethanolamine (NAE) molecule palmitoylethanolamide (PEA) is increased in plasma isolated from newly diagnosed BMS patients compared to healthy subjects, and that plasma PEA levels correlate with pain and depressive symptomatology (Barry *et al.*, 2018b). In fact, much evidence indicates that the eCB system can regulate nociceptive signalling and the immune response to inflammation, by acting both in the CNS and PNS. In addition, the peripheral eCB system is also closely associated with stress and/or depressive disorders (Hill *et al.*, 2013; Di Marzo *et al.*, 2015).

The contribution from oxidative stress must also be considered, given that stress-related hormonal alterations in post-menopausal BMS patients may affect MUC1 expression and burning pain perception (Kang *et al.*, 2017). Stress may, in fact, play a relevant role on BMS pathophysiology, since the stress-related enzyme α -amilase is also upregulated in saliva from BMS patients (Imura *et al.*, 2016; Nosratzahi *et al.*, 2017). Reports suggesting altered levels of reactive oxygen species (ROS) in saliva (Tvarijonaviciute *et al.*, 2017), in addition to alterations in total oxidant capacity and biological antioxidant potential as iron-reducing activity in blood (Tatullo *et al.*, 2012) of BMS patients, supports the contribution of oxidative stress to BMS pathogenesis.

2.3. Hormonal

During menopause, several changes occur in gonadal, adrenal and neuroactive steroid levels (Woda *et al.*, 2009), and the higher prevalence of BMS in peri- and postmenopausal women (Rabiei *et al.*, 2018) supports the role of female sex hormones in BMS pathogenesis. Indeed, hypoestrogenism at menopause is associated with xerostomia and taste alterations (Friedlander, 2002) as seen in BMS, and the salivary levels of 17β -estradiol in post-menopausal BMS patients correlates with the symptoms of the disorder (Kang *et al.*, 2017). The neuroendocrine stress response is controlled via the hypothalamic-pituitary-adrenal (HPA) axis, the activation of which promotes an increase in the levels of circulating corticosteroids to impact several systems (Pecoraro *et al.*, 2006) (**Figure 1**). Importantly, chronic stress can disrupt adrenal steroid production by impairing the supply of precursors for neuroactive steroids both in the skin, mucosa and nervous system (by glial cells in the CNS, and by Schwann cell in the PNS). The lower gonadal steroid production inherent to menopause, combined with chronic stress dysregulation, can contribute to irreversible neurodegenerative alteration in the PNS (small nerve fibres in oral mucosa) and/or CNS (Woda *et al.*, 2009). Since the production of protective neurosteroids is decreased, those regions may be more vulnerable to the action of corticoids (Woda *et al.*, 2009), which are increased in saliva from BMS patients (Kim *et al.*, 2012). Since these hormones can interact locally with benzodiazepine receptors, it may also explain the localization of pain in BMS (Pajot *et al.*, 2003; Dias Fernandes *et al.*, 2009). Furthermore, the over-production of cortisol may be a consequence of prolonged anxiety or stress (dysregulation of the HPA axis) (Koike *et al.*, 2014; Nosratzahi *et al.*, 2017), and both the excessive production and depletion of cortisol may be deleterious to neural tissues (Koike *et al.*, 2014).

The adrenal steroid dehydroepiandrosterone (DHEA) is an androgen and estrogen precursor associated with the production of male and female sex hormones. Interestingly, levels of this hormone are reduced in saliva from BMS patients, suggesting a possible correlation of DHEA deficiency with the development of disease (Dias Fernandes *et al.*, 2009). Although there is a clear correlation of menopause with BMS onset, it is likely that other factors must be present in combination with the hormonal imbalance for the disease onset, since hormone replacement therapy alone achieves conflicting outcomes (Zakrzewska *et al.*, 2005).

2.4. Psychological

Many BMS patients have suffered a stressful life event, either recently or in early life (Lamey *et al.*, 2005). While psychological disorders are not considered as causative factors in BMS, several studies have associated BMS with psychologic factors (somatization and psychoticism) (Yoo *et al.*, 2018), anxiety and depression (Davies *et al.*, 2016). Furthermore, BMS patients commonly present with characteristics of type C personality disorders, including fear and neurosis, in addition to low levels of novelty seeking (Taiminen *et al.*, 2011; Tokura *et al.*, 2015). Individuals with BMS also commonly report a fear of having cancer and commonly overreact to trivial stress stimulants (pain catastrophizing) (Rogulj *et al.*, 2014). Indeed, Kim and colleagues (2018) report that psychological factors increase the number and severity of BMS symptoms, especially in terms of taste disturbances (Kim *et al.*, 2018). Psychologic distress can also influence BMS pain perception (Yoshino *et al.*, 2017). It is interesting to note that many personality disorders, commonly observed in BMS, are associated with low dopaminergic tone in the CNS (Taiminen *et al.*, 2011). Indeed, chronic anxiety and stress promotes alterations in adrenal steroid physiology (Woda *et al.*, 2009). In terms of HPA dysfunction, BMS is associated with hypercortisolism (Amenabar *et al.*, 2008; Koike *et al.*, 2014), and reports suggest an inverse correlation between openness personality traits and stress-related salivary biomarkers, including cortisol, in BMS patients (de Souza *et al.*, 2015).

The correlation between BMS and psychological factors is under much investigation, with several contradictory reports published. Honda *et al.*, (2019) recently suggested that pain on the tongue in elderly female patients with BMS is more related to psychological factors than disturbances in mechanical sensitivity, since no QST alterations were determined (Honda *et al.*, 2019). Also, BMS patients that receive objective information and reassurance about their condition tend to be less negative, report lower pain and have a better QOL (Brailo *et al.*, 2016). This is supported by the responsiveness to anti-depressants and cognitive behavioural therapy (CBT) observed in this patient cohort (discussed in **section 3**). However, the former is not independent of the analgesic activity (Tu *et al.*, 2019), and the latter is usually correlated with better coping mechanisms rather than an aetiological cure (Zakrzewska & Buchanan, 2016). Moreover, BMS can occur without psychological problems, and furthermore the symptoms in BMS do not meet the criteria for a diagnosis of a formal psychiatric disorder (Kim *et al.*, 2018). In fact, the psychological distress in BMS may arise only after the pain symptoms, hence being more related to the delayed diagnosis. Overall, it is very difficult to ascertain the contribution of

psychological problems in BMS, leaving the question of a causal or aggravating factor in the pathophysiology of this syndrome (Kim & Kho, 2018).

3. BMS therapies

Although there are few data describing the natural course of the disease, the duration of symptoms in BMS can prolong for several years. When untreated, a small percentage of patients (approximately 3%) may achieve complete remission within five years after the onset of the clinical manifestations (Sardella *et al.*, 2006). The treatment of idiopathic BMS is challenging since there is limited evidence-based management strategies, and most therapeutic approaches yield limited success (Tu *et al.*, 2019). Indeed, data indicate that approximately 30% of the patients benefit from neuropathic pain medication (Sardella *et al.*, 2006). Clinically there is a reliance on drug therapies that target the clinical manifestations of the disease in combination with CBT (McMillan *et al.*, 2016).

The chronic pain, delayed diagnosis and lack of effective treatment greatly impair the QOL of BMS patients (Braud & Boucher, 2016). Moreover, patients that have previously experienced unsuccessful therapies tend to feel more negative emotions and report fewer positive results from new treatments (Varoni *et al.*, 2015). Therefore, there is a need for the clinician to inform and reassure the patient to avoid negative thinking and behavioural patterns (Brailo *et al.*, 2016). A full understanding of the pathophysiological mechanisms of the disease, together with a better diagnostic classification, will facilitate better disease management. As an example, current evidence indicates that a CNS-related BMS is more responsive to treatments that target the dopaminergic system (Carcamo Fonfria *et al.*, 2017), whereas a PNS-related BMS is more responsive to topical administration of the benzodiazepine clonazepam, in addition to nerve blockers (Gremeau-Richard *et al.*, 2010).

3.1. Pharmacological therapy

Several studies have investigated pharmacological approaches to manage BMS, but the number of well-designed trials to support pharmacological targets is limited (McMillan *et al.*, 2016; Liu *et al.*, 2018). Several authors consider tricyclic antidepressants the first-line therapeutic choice in BMS due to their wide use in other chronic neuropathic pain conditions (Moore *et al.*, 2015). α -Lipoic acid (an anti-oxidant), clonazepam (benzodiazepine) or gabapentin (anti-epileptic/anticonvulsant) are considered alternatives only when other medications are

contraindicated or poorly tolerated (Tu *et al.*, 2019). There is also increasing evidence that serotonin (5-HT) and noradrenaline (NA) reuptake inhibitors may be considered as an alternative treatment, particularly when patients are refractory to other medications. These pharmacological agents can act as analgesics by interacting with 5-HT, NA, gamma aminobutyric acid (GABA) and enkephalin descending pain signalling (Kim *et al.*, 2014; Mitsikostas *et al.*, 2017). Furthermore, capsaicin is also considered for the management of BMS due to its ability to reduce pain by decreasing the functionality of TRPV1 nociceptive signalling (Jorgensen & Pedersen, 2017). Elsewhere, alternative therapeutic strategies have been explored for BMS, including hormone replacement therapies (Tarkkila *et al.*, 2001), other antidepressants/antipsychotics (Takenoshita *et al.*, 2017), anaesthetics (Treldal *et al.*, 2016), lafutidine (histamine H2-receptor antagonist) (Toida *et al.*, 2009), benzydamine hydrochloride (nonsteroidal anti-inflammatory drug; NSAID) (Sardella *et al.*, 1999) and phytotherapeutic compounds (Valenzuela *et al.*, 2016). Unfortunately, there are limited controlled clinical studies to support the effectiveness of such compounds. Indeed, many studies concerning BMS therapeutics are not standardized, lacking clinically validated pain assessment tools specific to BMS, and consensus on how to effectively rate the pain associated with BMS. As a consequence, inconsistencies arise when comparing studies (McMillan *et al.*, 2016).

The most common pharmacological strategies currently employed in BMS, their mechanism of action, alongside adverse side effects, are listed in **Table 2**. From these pharmacological strategies, a recent systematic review (de Souza *et al.*, 2018) highlights clonazepam and α -lipoic acid as the only pharmacological compounds with the proclivity to significantly reduce BMS clinical manifestations compared to placebo in clinical trials. More recently a promising clinical study targeted the eCB-like compound PEA. In this study, BMS patients received a sublingual dose of ultramicrosized PEA (600 mg/twice daily; one sachet every 12 h) for 60 consecutive days. During this period, PEA exhibited significant pain-relieving efficacy when compared to the placebo group. Moreover, 4 months after ceasing PEA administration, this effect still persisted although less pronounced (Ottaviani *et al.*, 2018). Overall, data assessing the cannabinoid system as a bone fide therapeutic strategy in BMS are still lacking.

3.2. Non-pharmacological therapies

Non-pharmacological therapeutic strategies in BMS are diverse, and include low-level laser therapy (LLLT) (Al-Maweri *et al.*, 2017), repetitive transcranial magnetic stimulation (rTMS)

(Umezaki *et al.*, 2016), acupuncture (Jurisic Kvesic *et al.*, 2015), psychotherapy (Miziara *et al.*, 2009) and tongue protectors (a transparent polyethylene cover) (López-Jornet *et al.*, 2011). Although there is limited data published to date, LLLT poses some promise for reducing pain and symptoms in BMS, while being a non-invasive technique with no serious side effects. Indeed, LLLT demonstrates analgesic, anti-inflammatory and biostimulatory propensity due to an enhancement of 5-HT and β -endorphin synthesis and release, while reducing bradykinin secretion and blocking the depolarization of C fibers (Al-Maweri *et al.*, 2017). Also, evidence indicates that rTMS, when delivered over the dorsolateral prefrontal cortex, can reduce pain in BMS patients; however some patients report headaches as a side effect (Umezaki *et al.*, 2016). Some evidence, albeit limited, suggests that acupuncture can improve BMS symptoms (Jurisic Kvesic *et al.*, 2015). Overall, CBT has shown beneficial effects in at least one clinical trial (Zakrzewska *et al.*, 2003), and its combination with pharmacotherapy can also be beneficial (Femiano *et al.*, 2004). CBT focuses on educating BMS patients to parafunctional habits that are detrimental to their condition, such as clenching, bruxism and tongue habits (Matsuoka *et al.*, 2017). In addition, tongue protectors can be beneficial by controlling parafunctional habits for certain periods during the day (López-Jornet *et al.*, 2011). Overall, it is recommended that BMS patients should select oral care products that avoid formulations containing alcohol, flavouring agents and other known irritants, and should also improve their diet and sleep patterns (Tu *et al.*, 2019).

4. Potential use of cannabinoids for BMS

Cannabinoids include phytocannabinoids synthesised by the annual dioecious plant *Cannabis sativa* L. (*C. sativa*), endogenous cannabinoid ligands (the eCBs) and synthetic cannabinoid compounds (Lu & Mackie, 2016). The most common phytocannabinoids include Δ^9 -tetrahydrocannabinol (THC), a psychoactive phytocannabinoid, in addition to cannabiol (CBN) (an oxidized metabolite of THC), cannabidiol (CBD), cannabichromene (CBC) and cannabigerol (CBG) (Chandra *et al.*, 2017; Booth & Bohlmann, 2019). The eCBs represent a group of lipid messengers, synthesized on demand, that can interact with cannabinoid receptors in the eCB system. Examples include *N*-arachidonylethanolamine (anandamide; AEA), 2-arachidonoyl-glycerol (2-AG), *O*-arachidonoyl ethanolamine (virodhamine), *N*-arachidonoyl dopamine (NADA), and 2-arachidonoyl glycerol ether (noladin ether) (Storozhuk & Zholos, 2018). Lastly, synthetic cannabinoids are derivatives of the phytocannabinoids developed to exert receptor-specific effects within the eCB system, while reducing adverse psychoactive effects.

4.1. Cannabinoid targets

Cannabinoid molecules can exert their action by interacting with the eCB system both in the CNS and PNS. This system consists of two “classical” G-coupled protein receptors (GPCRs), CB₁ and CB₂, and other “non-classical” receptors, including the TRPV channel, orphan GPCRs (GPR119/GPR55) and nuclear peroxisome proliferator-activated receptors (PPARs) (Di Marzo *et al.*, 2015) (**Figure 2**). The “classical” CB₁ receptors are distributed predominantly throughout the nervous system, and are detected on a diverse array of cells/tissues in the body, including the immune, reproductive and digestive systems (Croxford, 2003). In contrast, CB₂ receptors are found primarily in the periphery, particularly located in cells/tissues of the immune system. However, under certain pathological conditions (i.e. nerve injury), CB₂ is expressed in some populations of neurons (Van Sickle *et al.*, 2005). Thus, CB₁ interaction is usually related to analgesic effects, while CB₂ signalling is commonly related to the immunomodulatory properties of these molecules (Pellati *et al.*, 2018). Depending on the structure, cannabinoid molecules have different affinities to these receptors, and can interact as agonists, antagonists and (or) inverse agonists. Resulting from these complex interactions, cannabinoid molecules can modulate multiple intracellular signalling pathways involving adenylyl cyclase (AC), mitogen-activated protein kinases (MAPKs), phosphoinositide 3-kinase (PI3K)/protein kinase B (PKB) and voltage-dependent ion channels (K⁺, Ca²⁺, Na⁺) (Demuth & Molleman, 2006). In terms of the “non-classical” receptors, TRPV1 is widely expressed in mammalian cells, mediating a variety of physiological processes including temperature sensation, pain and inflammation (Yoo *et al.*, 2019). Several studies have shown that the anti-inflammatory effects of cannabinoids are also mediated by PPAR activation (Paterniti *et al.*, 2013), which inhibit pro-inflammatory signalling pathways such as nuclear factor kappa B (NF-κB), and promote the expression of anti-inflammatory mediators (Cheng *et al.*, 2019). Moreover, activation of PPARα might also contribute to pain control by triggering TRPV1 signalling and its desensitization (Ambrosino *et al.*, 2014). Cannabinoids can also activate GPR55 receptor, which can control inflammation and pain (at the periphery), together with processes involved in memory, anxiety and glutamate release in the hippocampus (at the CNS) (Marichal-Cancino *et al.*, 2017).

4.2. Cannabinoid therapeutic properties

Cannabinoid-induced responses are complex due to the pharmacological differences in cannabinoid ligands and the involvement of multiple signalling mechanisms governing cannabinoid-mediated effects. Evidence shows that the eCB system has an important role in nervous system homeostasis and neuroprotection (Xu & Chen, 2015), and the use of cannabinoids afford a combination of neuroprotective, anti-inflammatory, antioxidative and anti-apoptotic properties (Iuvone *et al.*, 2004; Castillo *et al.*, 2010) (**Figure 2**). Considering the previously described pathophysiological mechanisms of BMS (**section 2**), such effects of cannabinoids might prove beneficial in the treatment of this syndrome and warrants full investigation.

4.2.1. Neuroprotection

Much evidence indicates that cannabinoids have neuroprotective properties in models of neurodegeneration. The eCB system is believed to play an important role in synaptic plasticity by regulating both excitatory and inhibitory synapses in response to certain events. These neurochemical changes contribute to processes such as learning, memory and behavioural adaptation (Xu & Chen, 2015). In particular, eCBs released in postsynaptic neurons suppress the release of neurotransmitters presynaptically. Therefore, cannabinoids may be beneficial in the treatment of BMS by preventing glutamate-induced excitotoxicity (Kano, 2014). In brain ischemic injury, cannabinoids can prevent neuronal damage and promote cell survival, by inhibiting mitochondrial dysfunction (Ma *et al.*, 2018). In neurodegenerative models, cannabinoids can also prevent oxidative stress-related neurotoxicity by modulating endoplasmic reticulum stress signalling (Vrechi *et al.*, 2018), reducing ROS accumulation, and lipid peroxidation (Iuvone *et al.*, 2004). Neuroprotection is also achieved by reducing neurodegeneration caused by neuroinflammatory processes (detailed in **section 4.2.3**) (Esposito *et al.*, 2007). Furthermore, some evidence, albeit limited, indicates that cannabinoids stimulate NGF (Velasco *et al.*, 2001) and brain-derived neurotrophic factor (BDNF) (D'Souza *et al.*, 2009) production. Considering the neuropathic nature of BMS, the neuroprotection afforded by cannabinoids represents a promising therapeutic strategy for BMS patients. Moreover, the role for neurotrophins in cannabinoid-mediated effects (and vice versa) may be critically important given that BMS patients exhibit important changes in GMV (Lee *et al.*, 2019).

4.2.2. Neurotransmission

As aforementioned, cannabinoids can also modulate neurotransmission, with associated effects on emotion, mood, anxiety and depression (Xu & Chen, 2015). Indeed, an understanding of role of the eCB system in depression and anxiety disorders has increased over the last number of years, and there is some indication of the therapeutical potential of cannabinoid-based drugs in disorders such as anxiety and posttraumatic stress disorders (Chadwick *et al.*, 2019). Adding to the inhibition of excitatory glutamatergic system (Colizzi *et al.*, 2016), several studies indicate that activation of CB₁ receptors can affect a large range of neurotransmitter systems, including dopamine, 5-HT, GABA, and NA signalling (Fantegrossi *et al.*, 2018; Mendiguren *et al.*, 2018). The eCB system is also a key player in the initiation/termination of HPA axis responses to stressful conditions, and much evidence supports the role of the eCB system as a regulator of the stress response (Morena *et al.*, 2016). Given the diverse roles of such systems in functional connectivity of the nervous system, pain processing, stress, cognition, mood and depression/anxiety, the impact of cannabinoids on these systems is critical in the consideration of BMS from a therapeutic standpoint. Importantly, our laboratory has shown that the expression of the eCB-like compound, PEA, is increased in plasma from BMS patients, and that this correlates with depressive symptomatology (Barry *et al.*, 2018b). PEA has potential anti-depressant effects (De Gregorio *et al.*, 2019), and the potential therapeutic role of PEA in BMS and neuropathic orofacial pain warrants full investigation.

Analgesia is one the principal therapeutic targets of the cannabinoid system, and multiple studies have demonstrated the efficacy of cannabinoids in the treatment of neuropathic pain (McDonough *et al.*, 2014). Indeed, some evidence indicates that the cannabis-based therapeutic Sativex® (discussed in **section 4.3**) can be useful in the management of trigeminal neuropathic pain (Gajofatto, 2016).

4.2.3. Anti-inflammatory

Cannabinoids demonstrate anti-inflammatory propensity in various disorders including Multiple Sclerosis (MS) (Annunziata *et al.*, 2017), traumatic brain injury (Braun *et al.*, 2018), spinal cord injury (Su *et al.*, 2017) and Parkinson's disease (Viveros-Paredes *et al.*, 2017). In these studies, the anti-inflammatory action of cannabinoids is predominantly mediated by activation of CB₂. Furthermore, *in vitro* data in CNS cells indicate that cannabinoids exert anti-inflammatory propensity against IFN- γ - (Ehrhart *et al.*, 2005), amyloid- β - (Esposito *et al.*, 2006), IL-1 β - (Sheng

et al., 2005) and toll-like receptor (TLR)- (Downer *et al.*, 2011) induced inflammation. Different cannabinoids can modulate proinflammatory cytokine and chemokine secretion by targeting several inflammatory mechanisms, including NF- κ B activation (Downer *et al.*, 2011), cyclooxygenase-2 (COX-2), inducible nitric oxide synthase (iNOS), and TNF- α (de Lago *et al.*, 2012). There is growing evidence that several inflammatory mediators are dysregulated in both plasma and saliva isolated from BMS patients, when compared to control subjects (Simčić *et al.*, 2006; Chen *et al.*, 2007; Pekiner *et al.*, 2008; Pezelj-Ribaric *et al.*, 2013; Barry *et al.*, 2018a), while polymorphisms in IL-1 β are associated with BMS pathogenesis (Guimaraes *et al.*, 2006). Therefore, modulation of these, and other proinflammatory molecules, is an important approach to consider in the management of BMS.

4.3. Cannabinoids in the clinic

Several cannabinoid-based therapies, including Sativex[®], Epidiolex[®], Marinol[®] and Cesamet[®], have been approved in several countries for use in the clinic for a range of disorders (details on indication, mechanism of action and side effects described in **Table 3**).

Sativex[®] is a combination of THC and CBD (2.7mg THC and 2.5mg CBD/0.1mL; 1:1 ratio) approved for the treatment of spasticity and pain in adult patients with MS (Feliu, 2015). The co-administration of both cannabinoids benefits from the mitigation of THC adverse effects (Vaney *et al.*, 2004). Sativex[®] is administered as an oromucosal spray, with the advantage of fast onset of action and high bioavailability (Scott *et al.*, 2013). Patients self-titrate the dosage according to their need and tolerance of the drug. Interestingly, a THC/CBD spray has been shown to produce an improvement in peripheral neuropathic (Serpell *et al.*, 2014). Also, a case study in an individual with MS receiving Sativex[®] for spasticity reported complete resolution of trigeminal neuralgia episodes and background facial discomfort, which were constantly present before treatment (Gajofatto, 2016).

Epidiolex[®], a purified solution of CBD (100mg/mL), is effective in the treatment of epileptic seizures, and has been approved for patients (2 years of age and older) with Lennox-Gastaut and Dravet syndromes (Ali *et al.*, 2019). In double-blind placebo-controlled trials, CBD demonstrates efficacy in reducing convulsive seizure frequency (Devinsky *et al.*, 2017). Since pure CBD is not associated with psychoactive properties, Epidiolex[®] is a particularly attractive therapeutic option.

Marinol® is a pharmaceutical formulation of synthetic THC (2.5mg, 5mg or 10mg soft gelatin capsules) indicated for anorexia associated with loss of appetite in AIDs patients, and for the treatment of nausea and vomiting in patients undergoing chemotherapy (Badowski & Yanful, 2018). Phase III studies assessing neuropathic pain symptoms in MS demonstrates a clinically relevant decrease in pain during a 16-week Marinol® treatment period, when compared to placebo (Schimrigk *et al.*, 2017).

Lastly, Cesamet®, a synthetic analogue of THC (1mg capsule), is approved in a number of countries for the treatment of chemotherapy-induced nausea and vomiting (Zurier & Burstein, 2016). Additionally, a number of trials have evaluated the efficacy of Cesamet® in the treatment of pain disorders, including neuropathic pain, chronic non-cancer pain and fibromyalgia (Corey C. Tsang, 2016). Reports indicate that Cesamet® has a higher bioavailability when compared to Marinol® (Turcott *et al.*, 2018).

5. Conclusion for future prespectives

BMS remains a true challenge for both patients and healthcare providers. Due to its multifactorial etiology and involvement of multiple physiological processes, its definitive diagnosis is difficult, and no cure for the disorder has been identified. There is an urgent need for well-designed translational research programmes to study the mechanisms underlying this syndrome, in addition to developing novel therapeutics in this area. Indeed, many studies concerning BMS therapeutics are not standardized, lacking clinically validated pain assessment tools specific to BMS, and consensus on how to effectively rate the pain associated with BMS. Therefore, inconsistencies arise when comparing studies. This review identifies cannabinoid-based therapeutics for consideration in the management/treatment of BMS. Given the known neuroprotective, anti-inflammatory, antioxidative and anti-apoptotic properties of cannabinoids, a full investigation of the cannabinoid system as a bone fide therapeutic strategy in BMS is warranted.

Acknowledgements

This work is supported by Enterprise Ireland (IP/2018/0740 to EJD).

Conflict of interest

The authors declare no conflict of interest.

Authors contributions

SRP, JTV, SD and EJD drafted the manuscript. BI, JPK and CM reviewed the original draft and provided additional input. All authors critically revised the manuscript and approved its final version.

6. Abbreviations

2-AG – 2-arachidonoyl-glycerol

5-HT – serotonin

AC – adenylyl cyclase

ACTH – adrenocorticotrophic hormone

AEA – anandamide

BDNF – brain-derived neurotrophic factor

BMS – burning mouth syndrome

CB – cannabinoid receptor

CBC – cannabichromene

CBD – cannabidiol

CBG – cannabigerol

CBN – cannabinol

CBT – cognitive behavioural therapy

CGRP – calcitonin gene related peptide

CNS – central nervous system

COX-2 – cyclooxygenase-2

CRH – corticotropin-releasing hormone

DHEA – dehydroepiandrosterone

eCB – endocannabinoid

GABA – gamma aminobutyric acid

GMV – gray matter volume

GPCRs – G-coupled protein receptors

HPA – hypothalamic-pituitary-adrenal

IFN- γ – interferon gamma

IL – interleukin
iNOS – inducible nitric oxide synthase
Klk13 – kallikrein 13
LLLT – low-level laser therapy
MAPKs – mitogen-activated protein kinases
mPFC – medial prefrontal cortex
MRI – magnetic resonance imaging
MS – multiple sclerosis
MUC1 – mucin 1
NA – noradrenaline
NADA – *N*-arachidonoyl dopamine
NAE – *N*-acylethanolamine
NF- κ B – nuclear factor kappa B
NGF – nerve growth factor
NSAID – nonsteroidal anti-inflammatory drug
PEA – palmitoylethanolamide
PI3K – phosphoinositide 3-kinase
PKB – protein kinase B
PNS – peripheral nervous system
PPARs – peroxisome proliferator-activated receptors
QOL – quality of life
QST – quantitative sensory thresholds
ROS – reactive oxygen species
rTMS – repetitive transcranial magnetic stimulation
SP – substance P
TG – trigeminal nerve
THC – Δ^9 -tetrahydrocannabinol
TLR – toll-like receptor
TNF- α – tumor necrosis factor alpha
TRPV1 - transient receptor potential vanilloid 1

7. References

- (2018) Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. *Cephalalgia : an international journal of headache*, **38**, 1-211.
- Acharya, S., Carlen, A., Wenneberg, B., Jontell, M. & Hagglin, C. (2018a) Clinical characterization of women with burning mouth syndrome in a case-control study. *Acta odontologica Scandinavica*, **76**, 279-286.
- Acharya, S., Hagglin, C., Jontell, M., Wenneberg, B., Ekstrom, J. & Carlen, A. (2018b) Saliva on the oral mucosa and whole saliva in women diagnosed with burning mouth syndrome. *Oral diseases*, **24**, 1468-1476.
- Adamo, D., Celentano, A., Ruoppo, E., Cucciniello, C., Pecoraro, G., Aria, M. & Mignogna, M.D. (2015) The Relationship Between Sociodemographic Characteristics and Clinical Features in Burning Mouth Syndrome. *Pain medicine (Malden, Mass.)*, **16**, 2171-2179.
- Adamo, D., Sardella, A., Varoni, E., Lajolo, C., Biasotto, M., Ottaviani, G., Vescovi, P., Simonazzi, T., Pentenero, M., Ardore, M., Spadari, F., Bombeccari, G., Montebugnoli, L., Gissi, D.B., Campisi, G., Panzarella, V., Carbone, M., Valpreda, L., Giuliani, M., Aria, M., Lo Muzio, L. & Mignogna, M.D. (2018) The association between burning mouth syndrome and sleep disturbance: A case-control multicentre study. *Oral diseases*, **24**, 638-649.
- Al-Maweri, S.A., Javed, F., Kalakonda, B., AlAizari, N.A., Al-Soneidar, W. & Al-Akwa, A. (2017) Efficacy of low level laser therapy in the treatment of burning mouth syndrome: A systematic review. *Photodiagnosis and photodynamic therapy*, **17**, 188-193.
- Albuquerque, R.J., de Leeuw, R., Carlson, C.R., Okeson, J.P., Miller, C.S. & Andersen, A.H. (2006) Cerebral activation during thermal stimulation of patients who have burning mouth disorder: an fMRI study. *Pain*, **122**, 223-234.

Ali, S., Scheffer, I.E. & Sadleir, L.G. (2019) Efficacy of cannabinoids in paediatric epilepsy. *Developmental medicine and child neurology*, **61**, 13-18.

Aljanobi, H., Sabharwal, A., Krishnakumar, B. & Kramer, J.M. (2017) Is it Sjogren's syndrome or burning mouth syndrome? Distinct pathoses with similar oral symptoms. *Oral surgery, oral medicine, oral pathology and oral radiology*, **123**, 482-495.

Ambrosino, P., Soldovieri, M.V., De Maria, M., Russo, C. & Taglialatela, M. (2014) Functional and biochemical interaction between PPARAlpha receptors and TRPV1 channels: Potential role in PPARAlpha agonists-mediated analgesia. *Pharmacological research*, **87**, 113-122.

Amenabar, J.M., Pawlowski, J., Hilgert, J.B., Hugo, F.N., Bandeira, D., Lhuller, F. & Lopes de Souza, M.A. (2008) Anxiety and salivary cortisol levels in patients with burning mouth syndrome: case-control study. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod*, **105**, 460-465.

Annunziata, P., Cioni, C., Mugnaini, C. & Corelli, F. (2017) Potent immunomodulatory activity of a highly selective cannabinoid CB2 agonist on immune cells from healthy subjects and patients with multiple sclerosis. *Journal of Neuroimmunology*, **303**, 66-74.

Badowski, M.E. & Yanful, P.K. (2018) Dronabinol oral solution in the management of anorexia and weight loss in AIDS and cancer. *Ther Clin Risk Manag*, **14**, 643-651.

Banu, S., Jabir, N.R., Mohan, R., Manjunath, N.C., Kamal, M.A., Kumar, K.R., Zaidi, S.K., Khan, M.S. & Tabrez, S. (2015) Correlation of Toll-like receptor 4, interleukin-18, transaminases, and uric acid in patients with chronic periodontitis and healthy adults. *J Periodontol*, **86**, 431-439.

Barry, A., O'Halloran, K.D., McKenna, J.P., McCreary, C. & Downer, E.J. (2018a) Plasma IL-8 signature correlates with pain and depressive symptomatology in patients with burning mouth syndrome: Results from a pilot study. *Journal of oral pathology & medicine : official*

publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology, **47**, 158-165.

Barry, A., O'Halloran, K.D., McKenna, J.P., McCreary, C., Harhen, B., Kerr, D.M., Finn, D.P. & Downer, E.J. (2018b) Plasma N-acylethanolamine and endocannabinoid levels in burning mouth syndrome: Potential role in disease pathogenesis. *Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology*, **47**, 440-442.

Bartoshuk, L.M., Snyder, D.J., Grushka, M., Berger, A.M., Duffy, V.B. & Kveton, J.F. (2005) Taste damage: previously unsuspected consequences. *Chem Senses*, **30 Suppl 1**, i218-219.

Bender, S.D. (2018) Burning Mouth Syndrome. *Dental clinics of North America*, **62**, 585-596.

Beneng, K., Yilmaz, Z., Yiangou, Y., McParland, H., Anand, P. & Renton, T. (2010) Sensory purinergic receptor P2X3 is elevated in burning mouth syndrome. *International journal of oral and maxillofacial surgery*, **39**, 815-819.

Booth, J.K. & Bohlmann, J. (2019) Terpenes in Cannabis sativa - From plant genomes to humans. *Plant Science*, **284**, 67-72.

Boras, V.V., Brailo, V., Lukac, J., Kordic, D. & Blazic-Potocki, Z. (2006) Salivary interleukin-6 and tumor necrosis factor-alpha in patients with burning mouth syndrome. *Oral diseases*, **12**, 353-355.

Boras, V.V., Savage, N.W., Brailo, V., Lukac, J., Lukac, M. & Alajbeg, I.Z. (2010) Salivary and serum levels of substance P, neurokinin A and calcitonin gene related peptide in burning mouth syndrome. *Medicina oral, patologia oral y cirugia bucal*, **15**, e427-431.

Borelli, V., Marchioli, A., Di Taranto, R., Romano, M., Chiandussi, S., Di Lenarda, R., Biasotto, M. & Zabucchi, G. (2010) Neuropeptides in saliva of subjects with burning mouth syndrome: a pilot study. *Oral diseases*, **16**, 365-374.

Borsani, E., Majorana, A., Cocchi, M.A., Conti, G., Bonadeo, S., Padovani, A., Lauria, G., Bardellini, E., Rezzani, R. & Rodella, L.F. (2014) Epithelial expression of vanilloid and cannabinoid receptors: a potential role in burning mouth syndrome pathogenesis. *Histology and histopathology*, **29**, 523-533.

Boucher, Y., Braud, A., Dufour, E., Agbo-Godeau, S., Baaroun, V., Descroix, V., Guinnepain, M.T., Ungeheuer, M.N., Ottone, C. & Rougeot, C. (2017) Opiorphin levels in fluids of burning mouth syndrome patients: a case-control study. *Clinical oral investigations*, **21**, 2157-2164.

Brailo, V., Firic, M., Vucicevic Boras, V., Andabak Rogulj, A., Krstevski, I. & Alajbeg, I. (2016) Impact of reassurance on pain perception in patients with primary burning mouth syndrome. *Oral diseases*, **22**, 512-516.

Braud, A. & Boucher, Y. (2016) The relationship between the clinical features of idiopathic burning mouth syndrome and self-perceived quality of life. *Journal of oral science*, **58**, 475-481.

Braud, A., Descroix, V., Ungeheuer, M.N., Rougeot, C. & Boucher, Y. (2017) Taste function assessed by electrogustometry in burning mouth syndrome: a case-control study. *Oral diseases*, **23**, 395-402.

Braun, M., Khan, Z.T., Khan, M.B., Kumar, M., Ward, A., Achyut, B.R., Arbab, A.S., Hess, D.C., Hoda, M.N., Baban, B., Dhandapani, K.M. & Vaibhav, K. (2018) Selective activation of cannabinoid receptor-2 reduces neuroinflammation after traumatic brain injury via alternative macrophage polarization. *Brain Behav Immun*, **68**, 224-237.

Browning, S., Hislop, S., Scully, C. & Shirlaw, P. (1987) The association between burning mouth syndrome and psychosocial disorders. *Oral Surg Oral Med Oral Pathol*, **64**, 171-174.

Cabras, T., Manconi, B., Castagnola, M., Sanna, M.T., Arba, M., Acharya, S., Ekstrom, J., Carlen, A. & Messina, I. (2019) Proteomics of the acid-soluble fraction of whole and major gland saliva in burning mouth syndrome patients. *Archives of oral biology*, **98**, 148-155.

Carcamo Fonfria, A., Gomez-Vicente, L., Pedraza, M.I., Cuadrado-Perez, M.L., Guerrero Peral, A.L. & Porta-Etessam, J. (2017) Burning mouth syndrome: Clinical description, pathophysiological approach, and a new therapeutic option. *Neurologia (Barcelona, Spain)*, **32**, 219-223.

Castillo, A., Tolon, M.R., Fernandez-Ruiz, J., Romero, J. & Martinez-Orgado, J. (2010) The neuroprotective effect of cannabidiol in an in vitro model of newborn hypoxic-ischemic brain damage in mice is mediated by CB(2) and adenosine receptors. *Neurobiol Dis*, **37**, 434-440.

Chadwick, V.L., Rohleder, C., Koethe, D. & Leweke, F.M. (2019) Cannabinoids and the endocannabinoid system in anxiety, depression, and dysregulation of emotion in humans. *Curr Opin Psychiatry*.

Chandra, S., Lata, H., Elsohly, M.A., Walker, L.A. & Potter, D. (2017) Cannabis cultivation: Methodological issues for obtaining medical-grade product. *Epilepsy & Behavior*, 302-312.

Chen, Q., Xia, J., Lin, M., Zhou, H. & Li, B. (2007) Serum interleukin-6 in patients with burning mouth syndrome and relationship with depression and perceived pain. *Mediators of inflammation*, **2007**, 45327.

Cheng, H.S., Tan, W.R., Low, Z.S., Marvalim, C., Lee, J.Y.H. & Tan, N.S. (2019) Exploration and Development of PPAR Modulators in Health and Disease: An Update of Clinical Evidence. *International journal of molecular sciences*, **20**.

Chimenos-Kustner, E., de Luca-Monasterios, F., Schemel-Suarez, M., Rodriguez de Rivera-Campillo, M.E., Perez-Perez, A.M. & Lopez-Lopez, J. (2017) Burning mouth syndrome and associated factors: A case-control retrospective study. *Medicina clinica*, **148**, 153-157.

Colizzi, M., McGuire, P., Pertwee, R.G. & Bhattacharyya, S. (2016) Effect of cannabis on glutamate signalling in the brain: A systematic review of human and animal evidence. *Neuroscience and biobehavioral reviews*, **64**, 359-381.

Corey C. Tsang, M.G.G. (2016) Nabilone for the Management of pain. *Pharmacotherapy*, 273-286.

Croxford, J.L. (2003) Therapeutic potential of cannabinoids in CNS disease. *CNS Drugs*, **17**, 179-202.

D'Souza, D.C., Pittman, B., Perry, E. & Simen, A. (2009) Preliminary evidence of cannabinoid effects on brain-derived neurotrophic factor (BDNF) levels in humans. *Psychopharmacology*, **202**, 569-578.

Davies, S.J., Underhill, H.C., Abdel-Karim, A., Christmas, D.M., Bolea-Alamanac, B.M., Potokar, J., Herrod, J. & Prime, S.S. (2016) Individual oral symptoms in burning mouth syndrome may be associated differentially with depression and anxiety. *Acta odontologica Scandinavica*, **74**, 155-160.

De Gregorio, D., Manchia, M., Carpiniello, B., Valtorta, F., Nobile, M., Gobbi, G. & Comai, S. (2019) Role of palmitoylethanolamide (PEA) in depression: Translational evidence: Special Section on "Translational and Neuroscience Studies in Affective Disorders". Section Editor, Maria Nobile MD, PhD. This Section of JAD focuses on the relevance of translational and neuroscience studies in providing a better understanding of the neural basis of affective disorders. The main aim is to briefly summaries relevant research

findings in clinical neuroscience with particular regards to specific innovative topics in mood and anxiety disorders. *J Affect Disord*, **255**.

de Lago, E., Moreno-Martet, M., Cabranes, A., Ramos, J.A. & Fernandez-Ruiz, J. (2012) Cannabinoids ameliorate disease progression in a model of multiple sclerosis in mice, acting preferentially through CB1 receptor-mediated anti-inflammatory effects. *Neuropharmacology*, **62**, 2299-2308.

de Souza, F.T., Kummer, A., Silva, M.L., Amaral, T.M., Abdo, E.N., Abreu, M.H., Silva, T.A. & Teixeira, A.L. (2015) The association of openness personality trait with stress-related salivary biomarkers in burning mouth syndrome. *Neuroimmunomodulation*, **22**, 250-255.

de Souza, I.F., Marmora, B.C., Rados, P.V. & Visioli, F. (2018) Treatment modalities for burning mouth syndrome: a systematic review. *Clinical oral investigations*, **22**, 1893-1905.

Demuth, D.G. & Molleman, A. (2006) Cannabinoid signalling. *Life sciences*, **78**, 549-563.

Devinsky, O., Cross, J., Laux, L., Marsh, E., Miller, I., R., N., Scheffer, I.E., Thiele, E. & Wright, S. (2017) Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome. *The New England Journal of Medicine*, **376**, 2011-2020.

Di Marzo, V., Stella, N. & Zimmer, A. (2015) Endocannabinoid signalling and the deteriorating brain. *Nat Rev Neurosci*, **16**, 30-42.

Dias Fernandes, C.S., Salum, F.G., Bandeira, D., Pawlowski, J., Luz, C. & Cherubini, K. (2009) Salivary dehydroepiandrosterone (DHEA) levels in patients with the complaint of burning mouth: a case-control study. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod*, **108**, 537-543.

Downer, E.J., Clifford, E., Gran, B., Nel, H.J., Fallon, P.G. & Moynagh, P.N. (2011) Identification of the synthetic cannabinoid R(+)-WIN55,212-2 as a novel regulator of IFN regulatory

factor 3 activation and IFN-beta expression: relevance to therapeutic effects in models of multiple sclerosis. *J Biol Chem*, **286**, 10316-10328.

Ehrenfeld, P., Bhoola, K.D., Matus, C.E. & Figueroa, C.D. (2018) Functional interrelationships between the kallikrein-related peptidases family and the classical kinin system in the human neutrophil. *Biol Chem*, **399**, 925-935.

Ehrhart, J., Obregon, D., Mori, T., Hou, H., Sun, N., Bai, Y., Klein, T., Fernandez, F., Tan, J. & Shytle, R.D. (2005) Stimulation of cannabinoid receptor 2 (CB2) suppresses microglial activation. *J Neuroinflammation*, **2**, 29.

Esposito, G., De Filippis, D., Maiuri, M.C., De Stefano, D., Carnuccio, R. & Iuvone, T. (2006) Cannabidiol inhibits inducible nitric oxide synthase protein expression and nitric oxide production in beta-amyloid stimulated PC12 neurons through p38 MAP kinase and NF-kappaB involvement. *Neurosci Lett*, **399**, 91-95.

Esposito, G., Scuderi, C., Savani, C., Steardo, L., Jr., De Filippis, D., Cottone, P., Iuvone, T., Cuomo, V. & Steardo, L. (2007) Cannabidiol in vivo blunts beta-amyloid induced neuroinflammation by suppressing IL-1beta and iNOS expression. *British journal of pharmacology*, **151**, 1272-1279.

Fantegrossi, W.E., Wilson, C.D. & Berquist, M.D. (2018) Pro-psychotic effects of synthetic cannabinoids: interactions with central dopamine, serotonin, and glutamate systems. *Drug Metab Rev*, **50**, 65-73.

Feliu, A., Moreno-Martet, M., Mecha M. Carrillo-Salinas, F. J., Lago, E., Fernandez-Ruiz, J. and Guaza, C. (2015) A Sativex-like combination of phytocannabinoids as a disease-modifying therapy in a viral model of multiple sclerosis. *British journal of pharmacology*.

Femiano, F., Gombos, F. & Scully, C. (2004) Burning Mouth Syndrome: open trial of psychotherapy alone, medication with alpha-lipoic acid (thioctic acid), and combination therapy. *Med Oral*, **9**, 8-13.

Forssell, H., Jaaskelainen, S., Tenovuo, O. & Hinkka, S. (2002) Sensory dysfunction in burning mouth syndrome. *Pain*, **99**, 41-47.

Friedlander, A.H. (2002) The physiology, medical management and oral implications of menopause. *J Am Dent Assoc*, **133**, 73-81.

Gajofatto, A. (2016) Refractory trigeminal neuralgia responsive to nabiximols in a patient with multiple sclerosis. *Mult Scler Relat Disord*, **8**, 64-65.

Giesecke, T., Gracely, R.H., Grant, M.A., Nachemson, A., Petzke, F., Williams, D.A. & Clauw, D.J. (2004) Evidence of augmented central pain processing in idiopathic chronic low back pain. *Arthritis Rheum*, **50**, 613-623.

Greteau-Richard, C., Dubray, C., Aublet-Cuvelier, B., Ughetto, S. & Woda, A. (2010) Effect of lingual nerve block on burning mouth syndrome (stomatodynia): a randomized crossover trial. *Pain*, **149**, 27-32.

Grushka, M., Sessle, B.J. & Howley, T.P. (1987) Psychophysical assessment of tactile, pain and thermal sensory functions in burning mouth syndrome. *Pain*, **28**, 169-184.

Guimaraes, A.L., de Sa, A.R., Victoria, J.M., de Fatima Correia-Silva, J., Gomez, M.V. & Gomez, R.S. (2006) Interleukin-1beta and serotonin transporter gene polymorphisms in burning mouth syndrome patients. *J Pain*, **7**, 654-658.

Haack, M., Simpson, N., Sethna, N., Kaur, S. & Mullington, J. (2019) Sleep deficiency and chronic pain: potential underlying mechanisms and clinical implications. *Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology*.

Hagelberg, N., Forssell, H., Rinne, J.O., Scheinin, H., Taiminen, T., Aalto, S., Luutonen, S., Nagren, K. & Jaaskelainen, S. (2003) Striatal dopamine D1 and D2 receptors in burning mouth syndrome. *Pain*, **101**, 149-154.

Hartmann, A., Seeberger, R., Bittner, M., Rolke, R., Welte-Jzyk, C. & Daublander, M. (2017) Profiling intraoral neuropathic disturbances following lingual nerve injury and in burning mouth syndrome. *BMC oral health*, **17**, 68.

Heckmann, S.M., Heckmann, J.G., Hilz, M.J., Popp, M., Marthol, H., Neundorfer, B. & Hummel, T. (2001) Oral mucosal blood flow in patients with burning mouth syndrome. *Pain*, **90**, 281-286.

Hill, M.N., Bierer, L.M., Makotkine, I., Golier, J.A., Galea, S., McEwen, B.S., Hillard, C.J. & Yehuda, R. (2013) Reductions in circulating endocannabinoid levels in individuals with post-traumatic stress disorder following exposure to the World Trade Center attacks. *Psychoneuroendocrinology*, **38**, 2952-2961.

Honda, M., Iida, T., Kamiyama, H., Masuda, M., Kawara, M., Svensson, P. & Komiyama, O. (2019) Mechanical sensitivity and psychological factors in patients with burning mouth syndrome. *Clinical oral investigations*, **23**, 757-762.

IHS (2018) Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. *Cephalalgia : an international journal of headache*, **38**, 1-211.

Imura, H., Shimada, M., Yamazaki, Y. & Sugimoto, K. (2016) Characteristic changes of saliva and taste in burning mouth syndrome patients. *Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology*, **45**, 231-236.

Iuvone, T., Esposito, G., Esposito, R., Santamaria, R., Di Rosa, M. & Izzo, A.A. (2004) Neuroprotective effect of cannabidiol, a non-psychoactive component from Cannabis

sativa, on beta-amyloid-induced toxicity in PC12 cells. *Journal of neurochemistry*, **89**, 134-141.

Jaaskelainen, S.K. (2018) Is burning mouth syndrome a neuropathic pain condition? *Pain*, **159**, 610-613.

Jaaskelainen, S.K., Lindholm, P., Valmunen, T., Pesonen, U., Taiminen, T., Virtanen, A., Lamusuo, S., Forssell, H., Hagelberg, N., Hietala, J. & Pertovaara, A. (2014) Variation in the dopamine D2 receptor gene plays a key role in human pain and its modulation by transcranial magnetic stimulation. *Pain*, **155**, 2180-2187.

Jaaskelainen, S.K. & Woda, A. (2017) Burning mouth syndrome. *Cephalalgia : an international journal of headache*, **37**, 627-647.

Ji, E.H., Diep, C., Liu, T., Li, H., Merrill, R., Messadi, D. & Hu, S. (2017) Potential protein biomarkers for burning mouth syndrome discovered by quantitative proteomics. *Molecular pain*, **13**, 1-8.

Jorgensen, M.R. & Pedersen, A.M. (2017) Analgesic effect of topical oral capsaicin gel in burning mouth syndrome. *Acta odontologica Scandinavica*, **75**, 130-136.

Jurisc Kvesic, A., Zavoreo, I., Basic Kes, V., Vucicevic Boras, V., Ciliga, D., Gabric, D. & Vrdoljak, D.V. (2015) The effectiveness of acupuncture versus clonazepam in patients with burning mouth syndrome. *Acupuncture in medicine : journal of the British Medical Acupuncture Society*, **33**, 289-292.

Kang, J.H., Kim, Y.Y., Chang, J.Y. & Kho, H.S. (2017) Relationships between oral MUC1 expression and salivary hormones in burning mouth syndrome. *Archives of oral biology*, **78**, 58-64.

Kano, M. (2014) Control of synaptic function by endocannabinoid-mediated retrograde signaling. *Proc Jpn Acad Ser B Phys Biol Sci*, **90**, 235-250.

Khan, S.A., Keaser, M.L., Meiller, T.F. & Seminowicz, D.A. (2014) Altered structure and function in the hippocampus and medial prefrontal cortex in patients with burning mouth syndrome. *Pain*, **155**, 1472-1480.

Kim, H.I., Kim, Y.Y., Chang, J.Y., Ko, J.Y. & Kho, H.S. (2012) Salivary cortisol, 17beta-estradiol, progesterone, dehydroepiandrosterone, and alpha-amylase in patients with burning mouth syndrome. *Oral diseases*, **18**, 613-620.

Kim, M.J. & Kho, H.S. (2018) Understanding of Burning Mouth Syndrome Based on Psychological Aspects. *The Chinese journal of dental research : the official journal of the Scientific Section of the Chinese Stomatological Association (CSA)*, **21**, 9-19.

Kim, M.J., Kim, J., Chang, J.Y., Kim, Y.Y. & Kho, H.S. (2017) Polymorphisms of interleukin-1beta and MUC7 genes in burning mouth syndrome. *Clinical oral investigations*, **21**, 949-955.

Kim, M.J., Kim, J. & Kho, H.S. (2018) Comparison between burning mouth syndrome patients with and without psychological problems. *International journal of oral and maxillofacial surgery*, **47**, 879-887.

Kim, Y.D., Lee, J.H. & Shim, J.H. (2014) Duloxetine in the treatment of burning mouth syndrome refractory to conventional treatment: A case report. *The Journal of international medical research*, **42**, 879-883.

Kizaki, T., Sato, S., Shirato, K., Sakurai, T., Ogasawara, J., Izawa, T., Ohira, Y., Suzuki, K. & Ohno, H. (2015) Effect of Circadian Rhythm on Clinical and Pathophysiological Conditions and Inflammation. *Crit Rev Immunol*, **35**, 261-275.

Kohorst, J.J., Bruce, A.J., Torgerson, R.R., Schenck, L.A. & Davis, M.D. (2014) A population-based study of the incidence of burning mouth syndrome. *Mayo Clinic proceedings*, **89**, 1545-1552.

Kohorst, J.J., Bruce, A.J., Torgerson, R.R., Schenck, L.A. & Davis, M.D.P. (2015) The prevalence of burning mouth syndrome: a population-based study. *The British journal of dermatology*, **172**, 1654-1656.

Koike, K., Shinozaki, T., Hara, K., Noma, N., Okada-Ogawa, A., Asano, M., Shinoda, M., Eliav, E., Gracely, R.H., Iwata, K. & Imamura, Y. (2014) Immune and endocrine function in patients with burning mouth syndrome. *Clin J Pain*, **30**, 168-173.

Kolkka-Palomaa, M., Jaaskelainen, S.K., Laine, M.A., Teerijoki-Oksa, T., Sandell, M. & Forssell, H. (2015) Pathophysiology of primary burning mouth syndrome with special focus on taste dysfunction: a review. *Oral diseases*, **21**, 937-948.

Lamey, P.J., Freeman, R., Eddie, S.A., Pankhurst, C. & Rees, T. (2005) Vulnerability and presenting symptoms in burning mouth syndrome. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod*, **99**, 48-54.

Lechner, J. & von Baehr, V. (2015) Peripheral Neuropathic Facial/Trigeminal Pain and RANTES/CCL5 in Jawbone Cavitation. *Evid Based Complement Alternat Med*, **2015**, 582520.

Lee, Y.C., Hong, I.K., Na, S.Y. & Eun, Y.G. (2015) Evaluation of salivary function in patients with burning mouth syndrome. *Oral diseases*, **21**, 308-313.

Lee, Y.C., Jahng, G.H., Ryu, C.W. & Byun, J.Y. (2019) Change in gray matter volume and cerebral blood flow in patients with burning mouth syndrome. *Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology*.

- Lewis, S.S., Grace, P.M., Hutchinson, M.R., Maier, S.F. & Watkins, L.R. (2017) Constriction of the buccal branch of the facial nerve produces unilateral craniofacial allodynia. *Brain Behav Immun*, **64**, 59-64.
- Liu, B.L., Yao, H., Zheng, X.J., Du, G.H., Shen, X.M., Zhou, Y.M. & Tang, G.Y. (2015) Low regional cerebral blood flow in burning mouth syndrome patients with depression. *Oral diseases*, **21**, 602-607.
- Liu, Y., Ho, R.C. & Mak, A. (2012) Interleukin (IL)-6, tumour necrosis factor alpha (TNF-alpha) and soluble interleukin-2 receptors (sIL-2R) are elevated in patients with major depressive disorder: a meta-analysis and meta-regression. *J Affect Disord*, **139**, 230-239.
- Liu, Y.F., Kim, Y., Yoo, T., Han, P. & Inman, J.C. (2018) Burning mouth syndrome: a systematic review of treatments. *Oral diseases*, **24**, 325-334.
- López-Jornet, P., Camacho-Alonso, F. & Andujar-Mateos, P. (2011) A prospective, randomized study on the efficacy of tongue protector in patients with burning mouth syndrome. *Oral diseases*, **17**, 277-282.
- Lopez-Jornet, P., Lucero-Berdugo, M., Castillo-Felipe, C., Zamora Lavella, C., Ferrandez-Pujante, A. & Pons-Fuster, A. (2015a) Assessment of self-reported sleep disturbance and psychological status in patients with burning mouth syndrome. *Journal of the European Academy of Dermatology and Venereology : JEADV*, **29**, 1285-1290.
- Lopez-Jornet, P., Molino Pagan, D., Andujar Mateos, P., Rodriguez Agudo, C. & Pons-Fuster, A. (2015b) Circadian rhythms variation of pain in burning mouth syndrome. *Geriatrics & gerontology international*, **15**, 490-495.
- Lu, H.C. & Mackie, K. (2016) An Introduction to the Endogenous Cannabinoid System. *Biological psychiatry*, **79**, 516-525.

Ma, L., Niu, W., Yang, S., Tian, J., Luan, H., Cao, M., Xi, W., Tu, W., Jia, J. & Lv, J. (2018) Inhibition of mitochondrial permeability transition pore opening contributes to cannabinoid type 1 receptor agonist ACEA-induced neuroprotection. *Neuropharmacology*, **135**, 211-222.

Marichal-Cancino, B.A., Fajardo-Valdez, A., Ruiz-Contreras, A.E., Mendez-Diaz, M. & Prospero-Garcia, O. (2017) Advances in the Physiology of GPR55 in the Central Nervous System. *Current neuropharmacology*, **15**, 771-778.

Marino, R., Capaccio, P., Pignataro, L. & Spadari, F. (2009) Burning mouth syndrome: the role of contact hypersensitivity. *Oral diseases*, **15**, 255-258.

Matsuoka, H., Chiba, I., Sakano, Y., Toyofuku, A. & Abiko, Y. (2017) Cognitive behavioral therapy for psychosomatic problems in dental settings. *BioPsychoSocial medicine*, **11**, 18.

McDonough, P., McKenna, J.P., McCreary, C. & Downer, E.J. (2014) Neuropathic orofacial pain: cannabinoids as a therapeutic avenue. *The international journal of biochemistry & cell biology*, **55**, 72-78.

McMillan, R., Forssell, H., Buchanan, J.A., Glenny, A.M., Weldon, J.C. & Zakrzewska, J.M. (2016) Interventions for treating burning mouth syndrome. *The Cochrane database of systematic reviews*, **11**, CD002779.

Mendiguren, A., Aostri, E. & Pineda, J. (2018) Regulation of noradrenergic and serotonergic systems by cannabinoids: relevance to cannabinoid-induced effects. *Life sciences*, **192**, 115-127.

Mitsikostas, D.D., Ljubisavljevic, S. & Deligianni, C.I. (2017) Refractory burning mouth syndrome: clinical and paraclinical evaluation, comorbiities, treatment and outcome. *The journal of headache and pain*, **18**, 40.

Miziara, I.D., Filho, B.C.A., Oliveira, R. & Rodrigues dos Santos, R.M. (2009) Group psychotherapy: An additional approach to burning mouth syndrome. *Journal of psychosomatic research*, **67**, 443-448.

Moghadam-Kia, S. & Fazel, N. (2017) A diagnostic and therapeutic approach to primary burning mouth syndrome. *Clinics in dermatology*, **35**, 453-460.

Moore, R.A., Derry, S., Aldington, D., Cole, P. & Wiffen, P.J. (2015) Amitriptyline for neuropathic pain in adults. *Cochrane Database of Systematic Reviews*.

Morena, M., Patel, S., Bains, J.S. & Hill, M.N. (2016) Neurobiological Interactions Between Stress and the Endocannabinoid System. *Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology*, **41**, 80-102.

Moura, B.S., Ferreira, N.D.R., DosSantos, M.F. & Janini, M.E.R. (2018) Changes in the vibration sensitivity and pressure pain thresholds in patients with burning mouth syndrome. *PloS one*, **13**, e0197834.

Naud, J.M., Benca, L., Drangsholt, M.T., LeResche, L. & Coldwell, S.E. (2018) A case-control evaluation of fungiform papillae density in burning mouth syndrome. *The Laryngoscope*, **128**, 841-846.

Ni Riordain, R., O'Dwyer, S. & McCreary, C. (2019) Burning mouth syndrome-a diagnostic dilemma. *Irish journal of medical science*.

Nosratzahi, T., Salimi, S. & Parvae, A. (2017) Comparison of Salivary Cortisol and alpha-amylase Levels and Psychological Profiles in Patients with Burning Mouth Syndrome. *Special care in dentistry : official publication of the American Association of Hospital Dentists, the Academy of Dentistry for the Handicapped, and the American Society for Geriatric Dentistry*, **37**, 120-125.

Ottaviani, G., Rupel, K., Gobbo, M., Poropat, A., Zoi, V., Faraon, M., Di Lenarda, R. & Biasotto, M. (2018) Efficacy of ultramicronized palmitoylethanolamide in burning mouth syndrome-affected patients: a preliminary randomized double-blind controlled trial. *Clinical oral investigations*.

Pajot, J., Ressot, C., Ngom, I. & Woda, A. (2003) Gonadectomy induces site-specific differences in nociception in rats. *Pain*, **104**, 367-373.

Paterniti, I., Impellizzeri, D., Crupi, R., Morabito, R., Campolo, M., Esposito, E. & Cuzzocrea, S. (2013) Molecular evidence for the involvement of PPAR-delta and PPAR-gamma in anti-inflammatory and neuroprotective activities of palmitoylethanolamide after spinal cord trauma. *J Neuroinflammation*, **10**, 20.

Pecoraro, N., Dallman, M.F., Warne, J.P., Ginsberg, A.B., Laugero, K.D., la Fleur, S.E., Houshyar, H., Gomez, F., Bhargava, A. & Akana, S.F. (2006) From Malthus to motive: how the HPA axis engineers the phenotype, yoking needs to wants. *Prog Neurobiol*, **79**, 247-340.

Pekiner, F.N., Demirel, G.Y., Gumru, B. & Ozbayrak, S. (2008) Serum cytokine and T regulatory cell levels in patients with burning mouth syndrome. *Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology*, **37**, 528-534.

Pellati, F., Borgonetti, V., Brighenti, V., Biagi, M., Benvenuti, S. & Corsi, L. (2018) Cannabis sativa L. and Nonpsychoactive Cannabinoids: Their Chemistry and Role against Oxidative Stress, Inflammation, and Cancer. *BioMed research international*, **2018**, 1691428.

Pezelj-Ribaric, S., Kqiku, L., Brumini, G., Urek, M.M., Antonic, R., Kuis, D., Glazar, I. & Stadtler, P. (2013) Proinflammatory cytokine levels in saliva in patients with burning mouth syndrome before and after treatment with low-level laser therapy. *Lasers in medical science*, **28**, 297-301.

Puhakka, A., Forssell, H., Soinila, S., Virtanen, A., Roytta, M., Laine, M., Tenovuo, O., Teerijoki-Oksa, T. & Jaaskelainen, S.K. (2016) Peripheral nervous system involvement in primary burning mouth syndrome--results of a pilot study. *Oral diseases*, **22**, 338-344.

Rabiei, M., Leili, E.K. & Alizadeh, L. (2018) Burning Mouth Syndrome: A Comparative Cross-sectional Study. *Contemporary clinical dentistry*, **9**, S256-S260.

Robinson, L.R. (2000) Traumatic injury to peripheral nerves. *Muscle Nerve*, **23**, 863-873.

Rogulj, A.A., Richter, I., Brailo, V., Krstevski, I. & Boras, V.V. (2014) CATASTROPHIZING IN PATIENTS WITH BURNING MOUTH SYNDROME. *Acta stomatologica Croatica*, **48**, 109-115.

Salaric, I., Sabalic, M. & Alajbeg, I. (2017) Opiorphin in burning mouth syndrome patients: a case-control study. *Clinical oral investigations*, **21**, 2363-2370.

Sardella, A., Lodi, G., Demarosi, F., Bez, C., Cassano, S. & Carrassi, A. (2006) Burning mouth syndrome: a retrospective study investigating spontaneous remission and response to treatments. *Oral diseases*, **12**, 152-155.

Sardella, A., Uglietti, D., Demarosi, F., Lodi, G., Bez, C. & Carrassi, A. (1999) Benzydamine hydrochloride oral rinses in management of burning mouth syndrome: A clinical trial. *Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontology*, **88**, 683-686.

Schimrigk, S., Marziniak, M., Neubauer, C., Kugler, E., Werner, G. & Abramov-Sommariva, D. (2017) Dronabinol Is a Safe Long-Term Treatment Option for Neuropathic Pain Patients. *European Neurology*.

Schobel, N., Kyereme, J., Minovi, A., Dazert, S., Bartoshuk, L. & Hatt, H. (2012) Sweet taste and chorda tympani transection alter capsaicin-induced lingual pain perception in adult human subjects. *Physiology & behavior*, **107**, 368-373.

Scott, C.G., White, L., White, S., Wilbraham, D. & Guy, G.W. (2013) A phase I study to assess the single and multiple dose pharmacokinetic of THC/CBD oromucosal spray. *European Journal of Clinical Pharmacology*, **69**, 1135-1147.

Serpell, M., Ratcliffe, S., Hovorka, J., Schofield, M., Taylor, L., Lauder, H. & Ehler, E. (2014) A double-blind, randomized, placebo-controlled, parallel group study of THC/CBD spray in peripheral neuropathic pain treatment. *Eur J Pain*, **18**, 999-1012.

Sheng, W.S., Hu, S., Min, X., Cabral, G.A., Lokensgard, J.R. & Peterson, P.K. (2005) Synthetic cannabinoid WIN55,212-2 inhibits generation of inflammatory mediators by IL-1 β -stimulated human astrocytes. *Glia*, **49**, 211-219.

Shinoda, M., Takeda, M., Honda, K., Maruno, M., Katagiri, A., Satoh-Kuriwada, S., Shoji, N., Tsuchiya, M. & Iwata, K. (2015) Involvement of peripheral artemin signaling in tongue pain: possible mechanism in burning mouth syndrome. *Pain*, **156**, 2528-2537.

Sikora, M., Verzak, Z., Matijevic, M., Vcev, A., Siber, S., Music, L. & Carek, A. (2018) Anxiety and Depression Scores in Patients with Burning Mouth Syndrome. *Psychiatria Danubina*, **30**, 466-470.

Simčić, D., Pezelj-Ribarić, S., Grzić, R., Horvat, J., Brumini, G. & Muhvić-Urek, M. (2006) Detection of salivary interleukin 2 and interleukin 6 in patients with burning mouth syndrome. *Mediators of inflammation*, **2006**, 54632.

Sinding, C., Gransjoen, A.M., Schlumberger, G., Grushka, M., Frasnelli, J. & Singh, P.B. (2016) Grey matter changes of the pain matrix in patients with burning mouth syndrome. *The European journal of neuroscience*, **43**, 997-1005.

Storozhuk, M.V. & Zholos, A.V. (2018) TRP Channels as Novel Targets for Endogenous Ligands: Focus on Endocannabinoids and Nociceptive Signalling. *Current neuropharmacology*, **16**, 137-150.

Su, B.X., Chen, X., Huo, J., Guo, S.Y., Ma, R. & Liu, Y.W. (2017) The synthetic cannabinoid WIN55212-2 ameliorates traumatic spinal cord injury via inhibition of GAPDH/Siah1 in a CB2-receptor dependent manner. *Brain research*, **1671**, 85-92.

Suh, K.I., Kim, Y.K. & Kho, H.S. (2009) Salivary levels of IL-1beta, IL-6, IL-8, and TNF-alpha in patients with burning mouth syndrome. *Archives of oral biology*, **54**, 797-802.

Taiminen, T., Kuusalo, L., Lehtinen, L., Forssell, H., Hagelberg, N., Tenovuo, O., Luutonen, S., Pertovaara, A. & Jaaskelainen, S. (2011) Psychiatric (axis I) and personality (axis II) disorders in patients with burning mouth syndrome or atypical facial pain. *Scand J Pain*, **2**, 155-160.

Tait, R.C., Ferguson, M. & Herndon, C.M. (2017) Chronic Orofacial Pain: Burning Mouth Syndrome and Other Neuropathic Disorders. *Journal of pain management & medicine*, **3**.

Takenoshita, M., Motomura, H. & Toyofuku, A. (2017) Low-Dose Aripiprazole Augmentation in Amitriptyline-Resistant Burning Mouth Syndrome: Results from Two Cases. *Pain medicine (Malden, Mass.)*, **18**, 814-815.

Tarkkila, L., Linna, M., Tiitinen, A., Lindqvist, C. & Meurman, J.H. (2001) Oral symptoms at menopause--the role of hormone replacement therapy. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod*, **92**, 276-280.

Tatullo, M., Marrelli, M., Scacco, S., Lorusso, M., Doria, S., Sabatini, R., Auteri, P., Cagiano, R. & Inchingolo, F. (2012) *Relationship between oxidative stress and 'burning mouth syndrome' in female patients: A scientific hypothesis.*

Toida, M., Kato, K., Makita, H., Long, N.K., Takeda, T., Hatakeyama, D., Yamashita, T. & Shibata, T. (2009) Palliative effect of lafutidine on oral burning sensation. *Journal of Oral Pathology & Medicine*, **38**, 262-268.

Tokura, T., Kimura, H., Ito, M., Nagashima, W., Sato, N., Kimura, Y., Arao, M., Aleksic, B., Yoshida, K., Kurita, K. & Ozaki, N. (2015) Temperament and character profiles of patients with burning mouth syndrome. *Journal of psychosomatic research*, **78**, 495-498.

Tredal, C., Jacobsen, C.B., Mogensen, S., Rasmussen, M., Jacobsen, J., Petersen, J., Lynge Pedersen, A.M. & Andersen, O. (2016) Effect of a local anesthetic lozenge in relief of symptoms in burning mouth syndrome. *Oral diseases*, **22**, 123-131.

Tu, T.T.H., Takenoshita, M., Matsuoka, H., Watanabe, T., Suga, T., Aota, Y., Abiko, Y. & Toyofuku, A. (2019) Current management strategies for the pain of elderly patients with burning mouth syndrome: a critical review. *BioPsychoSocial medicine*, **13**, 1.

Turcott, J.G., del Rocío, G.N.M., Flores-Estrada, D. & al, e. (2018) The effect of nabilone on appetite, nutritional status, and quality of life in lung cancer patients: a randomized, double-blind clinical trial *Supportive Care in Cancer*, **26**, 3029-3038.

Tvarijonaviciute, A., Aznar-Cayuela, C., Rubio, C.P., Ceron, J.J. & Lopez-Jornet, P. (2017) Evaluation of salivary oxidate stress biomarkers, nitric oxide and C-reactive protein in patients with oral lichen planus and burning mouth syndrome. *Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology*, **46**, 387-392.

Umezaki, Y., Badran, B.W., DeVries, W.H., Moss, J., Gonzales, T. & George, M.S. (2016) The Efficacy of Daily Prefrontal Repetitive Transcranial Magnetic Stimulation (rTMS) for Burning Mouth Syndrome (BMS): A Randomized Controlled Single-blind Study. *Brain stimulation*, **9**, 234-242.

Valenca, M.M., de Oliveira, D.A. & Martins, H.A. (2015) Alice in Wonderland Syndrome, Burning Mouth Syndrome, Cold Stimulus Headache, and HaNDL: Narrative Review. *Headache*, **55**, 1233-1248.

Valenzuela, S., Pons-Fuster, A. & Lopez-Jornet, P. (2016) Effect of a 2% topical chamomile application for treating burning mouth syndrome: a controlled clinical trial. *Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology*, **45**, 528-533.

Van Sickle, M.D., Duncan, M., Kingsley, P.J., Mouihate, A., Urbani, P., Mackie, K., Stella, N., Makriyannis, A., Piomelli, D., Davison, J.S., Marnett, L.J., Di Marzo, V., Pittman, Q.J., Patel, K.D. & Sharkey, K.A. (2005) Identification and functional characterization of brainstem cannabinoid CB2 receptors. *Science*, **310**, 329-332.

Vaney, C., Heinzl-Gutenbrunner, M., Jobin, P., Tschopp, F., Gattlen, B., Hagen, U., Schnelle, M. & Reif, M. (2004) Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover study. *Multiple Sclerosis*, 417-424.

Varoni, E.M., Lodi, G. & Sardella, A. (2015) The placebo effect might affect treatment expectations in patients with burning mouth syndrome. *Pain*, **156**, 356.

Velasco, L., Ruiz, L., Sanchez, M.G. & Diaz-Laviada, I. (2001) delta(9)-Tetrahydrocannabinol increases nerve growth factor production by prostate PC-3 cells. Involvement of CB1 cannabinoid receptor and Raf-1. *Eur J Biochem*, **268**, 531-535.

Viveros-Paredes, J.M., Gonzalez-Castaneda, R.E., Gertsch, J., Chaparro-Huerta, V., Lopez-Roa, R.I., Vazquez-Valls, E., Beas-Zarate, C., Camins-Espuny, A. & Flores-Soto, M.E. (2017) Neuroprotective Effects of beta-Caryophyllene against Dopaminergic Neuron Injury in a Murine Model of Parkinson's Disease Induced by MPTP. *Pharmaceuticals (Basel)*, **10**.

Vrechi, T.A., Crunfli, F., Costa, A.P. & Torrao, A.S. (2018) Cannabinoid Receptor Type 1 Agonist ACEA Protects Neurons from Death and Attenuates Endoplasmic Reticulum Stress-Related Apoptotic Pathway Signaling. *Neurotox Res*, **33**, 846-855.

Wada, A., Shizukuishi, T., Kikuta, J., Yamada, H., Watanabe, Y., Imamura, Y., Shinozaki, T., Dezawa, K., Haradome, H. & Abe, O. (2017) Altered structural connectivity of pain-related brain network in burning mouth syndrome-investigation by graph analysis of probabilistic tractography. *Neuroradiology*, **59**, 525-532.

Watanabe, K., Noma, N., Sekine, N., Takanezawa, D., Hirota, C., Eliav, E. & Imamura, Y. (2018) Association of somatosensory dysfunction with symptom duration in burning mouth syndrome. *Clinical oral investigations*.

Wisner, A., Dufour, E., Messaoudi, M., Nejdi, A., Marcel, A., Ungeheuer, M.N. & Rougeot, C. (2006) Human Opiorphin, a natural antinociceptive modulator of opioid-dependent pathways. *Proc Natl Acad Sci U S A*, **103**, 17979-17984.

Woda, A., Dao, T. & Gremeau-Richard, C. (2009) Steroid dysregulation and stomatodynia (burning mouth syndrome). *J Orofac Pain*, **23**, 202-210.

Wood, P.B. (2008) Role of central dopamine in pain and analgesia. *Expert Rev Neurother*, **8**, 781-797.

Xu, J.Y. & Chen, C. (2015) Endocannabinoids in synaptic plasticity and neuroprotection. *Neuroscientist*, **21**, 152-168.

Yilmaz, Z., Egbuniwe, O. & Renton, T. (2016) The Detection of Small-Fiber Neuropathies in Burning Mouth Syndrome and Iatrogenic Lingual Nerve Injuries: Use of Quantitative Sensory Testing. *J Oral Facial Pain Headache*, **30**, 87-98.

Yilmaz, Z., Renton, T., Yiangou, Y., Zakrzewska, J., Chessell, I.P., Bountra, C. & Anand, P. (2007) Burning mouth syndrome as a trigeminal small fibre neuropathy: Increased heat and capsaicin receptor TRPV1 in nerve fibres correlates with pain score. *J Clin Neurosci*, **14**, 864-871.

Yoo, H.S., Jin, S.H., Lee, Y.J., Song, C.M., Ji, Y.B. & Tae, K. (2018) The role of psychological factors in the development of burning mouth syndrome. *International journal of oral and maxillofacial surgery*, **47**, 374-378.

Yoo, M.H., Rhee, Y.H., Jung, J., Lee, S.J., Moon, J.H., Mo, J.H. & Chung, P.S. (2019) TRPV1 regulates inflammatory process in the tongue of surgically induced xerostomia mouse. *Head Neck*.

Yoshino, A., Okamoto, Y., Doi, M., Okada, G., Takamura, M., Ichikawa, N. & Yamawaki, S. (2017) Functional Alterations of Postcentral Gyrus Modulated by Angry Facial Expressions during Intraoral Tactile Stimuli in Patients with Burning Mouth Syndrome: A Functional Magnetic Resonance Imaging Study. *Frontiers in psychiatry*, **8**, 224.

Zakrzewska, J. & Buchanan, J.A. (2016) Burning mouth syndrome. *BMJ clinical evidence*, **2016**.

Zakrzewska, J.M., Forssell, H. & Glenny, A.M. (2003) Interventions for the treatment of burning mouth syndrome: a systematic review. *J Orofac Pain*, **17**, 293-300.

Zakrzewska, J.M., Forssell, H. & Glenny, A.M. (2005) Interventions for the treatment of burning mouth syndrome. *Cochrane Database of Systematic Reviews*.

Zidverc-Trajkovic, J., Stanimirovic, D., Obrenovic, R., Tajti, J., Vecsei, L., Gardi, J., Nemeth, J., Mijajlovic, M., Sternic, N. & Jankovic, L. (2009) Calcitonin gene-related peptide levels in saliva of patients with burning mouth syndrome. *Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology*, **38**, 29-33.

Zurier, R.B. & Burstein, S.H. (2016) Cannabinoids, inflammation, and fibrosis. *FASEB journal : official publication of the Federation of American Societies for Experimental Biology*, **30**, 3682-3689.

8. Tables

Table 1: Factors correlated with BMS onset

Local Factors	Systemic Factors
<ul style="list-style-type: none"> • Odontogenic or mucosal disease • Mechanical or chemical irritation • Hypersensitivity reactions • Viral, fungal or bacterial infection • Xerostomia • Parafunctional habits • Dentures • Candidiasis 	<ul style="list-style-type: none"> • Nutritional and vitamin deficiencies (<i>vitamin B12, folic acid, iron, and zinc</i>) • Autoimmune, gastrointestinal and endocrine disorders (<i>diabetes mellitus, gastrointestinal reflux, hormonal changes and thyroid dysfunction</i>) • Pharmacotherapeutic agents (<i>angiotensin-converting enzyme inhibitors</i>)

Table 2: BMS pharmacological therapies

Pharmacological Therapies		Mechanism of Action	Adverse effects
Systemic	Antidepressants	Tricyclic antidepressants <ul style="list-style-type: none"> • <i>Amitriptyline</i> 	<ul style="list-style-type: none"> • Dry mouth • Drowsiness, fatigue • Weight gain
		Serotonin and/or Norepinephrine reuptake inhibitors <ul style="list-style-type: none"> • <i>Duloxetine</i> • <i>Venlafaxine</i>(Mitsikostas <i>et al.</i>, 2017) • <i>Milnacipran</i> 	<ul style="list-style-type: none"> • Dizziness, drowsiness • Constipation • Withdrawal symptoms
	Benzodiazepines	<ul style="list-style-type: none"> • Sedative, anxiolytic, analgesic • Agonist for GABA receptors (CNS and PNS*) • Activates pain-inhibitory pathways at the CNS • ↓ excitability of peripheral sensory nerve fibres* 	<ul style="list-style-type: none"> • Sedation, somnolence, fatigue, dizziness • Dependence (low risk) • Topic minimal adverse effects*
*Also topical (short effect duration)			

Topical	Anticonvulsants <ul style="list-style-type: none"> • <i>Gabapentin</i>** <p>**Alone or in combination with <i>α-Lipoic Acid</i></p>	<ul style="list-style-type: none"> • Pain relief • GABA agonist (CNS) • ↓ mono-amine neurotransmitters release • Inhibits voltage-dependent Ca^{2+} channel subunit $\alpha 2\delta-1/2$ • ↓ CNS activity 	<ul style="list-style-type: none"> • Mild adverse effects • Dose-dependent adverse effects • Somnolence, fatigue, dizziness, nausea, and mood swings
	Vitamin-like antioxidants <ul style="list-style-type: none"> • <i>α-Lipoic acid</i> 	<ul style="list-style-type: none"> • Neuroprotective effect and pain relief • Antioxidant (↑ glutathione levels) and free radical scavenger • Stimulate the production of NGF and nerve regeneration • ↓ blood glucose levels • Modulate inflammatory NF-κB signalling 	<ul style="list-style-type: none"> • Mild adverse effects • Nausea, vomiting and vertigo
	Local anaesthetics/ Non-steroidal anti-inflammatories <ul style="list-style-type: none"> • <i>Capsaicin</i> 	<ul style="list-style-type: none"> • ↓ oral burning sensation and neuropathic inflammation • Desensitizes nociceptors via TRPV1 binding in peripheral small fibers • ↓ biosynthesis of neurotransmitters • ↓ neuropeptide stores (CGRP and SP) 	<ul style="list-style-type: none"> • Gastric pain • Poor patient tolerability

Table 3: Cannabinoids licensed in clinic


Name	Composition	Indication	Administration Route	Postulated mechanism of action	Common Side Effects
Sativex®	THC:CBD <i>1:1</i>	<ul style="list-style-type: none"> • MS (spasticity) • Cancer pain • Neuropathic pain 	<ul style="list-style-type: none"> • Oral spray 	<ul style="list-style-type: none"> • Cannabinoid receptors: CB1, CB2 • G-protein coupled receptors: GPR55, 5HT1A • Ion channels: GlyR, Cav3.x, VDAC1 	<ul style="list-style-type: none"> • Dizziness • Fatigue
Epidiolex®	CBD <i>(highly purified)</i>	<ul style="list-style-type: none"> • Lennox-Gastaut syndrome • Dravet syndrome <i>(Antiepileptic for treatment of seizures)</i> 	<ul style="list-style-type: none"> • Oral solution 	<ul style="list-style-type: none"> • G-protein coupled receptors: GPR55, 5HT1A • Ion channels: GlyR, Cav3.x, VDAC1 	<ul style="list-style-type: none"> • Somnolence, • Diarrhea • Decreased appetite
Marinol® (Dronabinol)	THC	<ul style="list-style-type: none"> • Loss of appetite in AIDS patients • Chemotherapy 	<ul style="list-style-type: none"> • Capsule • Oral Solution 	<ul style="list-style-type: none"> • Cannabinoid receptors: CB1, CB2 	<ul style="list-style-type: none"> • Drowsiness, dizziness • Dry mouth

		induced nausea and vomiting			• Euphoria
Cesamet® (Nabilone)	<i>Synthetic analogue of THC</i>	• Chemotherapy induced nausea and vomiting	• Capsule	• Cannabinoid receptors: CB1, CB2	• Drowsiness, dizziness • Dry mouth • Euphoria


9. Figure captions

Figure 1: Pathophysiological mechanisms in BMS. BMS patients present significant alterations at the CNS, including (A) different patterns of connectivity between brain areas associated with pain processing, and (B) alterations of the striatal dopaminergic signalling. (C) At the PNS, many patients demonstrate trigeminal dysfunction, peripheral small fibre damage and altered activity of local receptors. Recent data has shed light on the neuroinflammatory mechanism of this syndrome. (D, E) Dysregulation in the production of pro-inflammatory cytokines and chemokines, associated with oxidative stress damage, can contribute to, and aggravate, neuropathic pain. Lastly, (F) HPA axis dysregulation due to chronic stress, in combination with a lower gonadal steroid production inherent to menopause, may also contribute to BMS pathogenesis.

Figure 2: Cannabinoid mechanisms of action relevant to BMS. Both plant-derived cannabinoids and eCBs can interact with “classical” and “non-classical” CB receptors. This interaction can promote neuronal plasticity, cell survival and modulate neurotransmission, with associated effects on pain, anxiety and depression. Cannabinoids also modulate inflammatory and oxidative signalling pathways relevant in BMS pathophysiology, including NF-κB and MAPK signalling.



ejn_14712_f1.tif



ejn_14712_f2.tif